Pharmaron Beijing Co., Ltd.

康龍化成(北京)新藥技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3759)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026

FINANCIAL SUMMARY AND HIGHLIGHTS

	Six months ended June 30,		
	2026	2025	Change
	RMB'000	*RMB'000*	*%*
Revenue	**7,595,424**	6,440,951	17.9
Gross profit	**2,474,869**	2,172,201	13.9
Profit attributable to owners of the parent	**750,194**	701,396	7.0
Non-IFRSs adjusted net profit attributable to owners of the parent	**909,013**	755,701	20.3
Net cash flows generated from operating activities	**1,084,645**	1,408,277	(23.0)

– During the Reporting Period, the Group recorded aggregate revenue of approximately RMB7,595.4 million, representing an increase of approximately RMB1,154.5 million, or 17.9%, as compared to the six months ended June 30, 2025.

– During the Reporting Period, the profit attributable to owners of the parent was approximately RMB750.2 million, representing an increase of approximately 7.0% as compared to the six months ended June 30, 2025.

– During the Reporting Period, the net cash flows generated from operating activities were approximately RMB1,084.6 million, representing a decrease of approximately 23.0% as compared to the six months ended June 30, 2025.

– The Board resolved not to declare any interim dividend for the six months ended June 30, 2026.

The Board of Pharmaron Beijing Co., Ltd. is pleased to announce the unaudited interim results of the Group for the six months ended June 30, 2026, together with the comparative figures for the corresponding period in 2025.

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

FOR THE SIX MONTHS ENDED JUNE 30, 2026

	Notes	Six months ended June 30, 2026 **RMB'000** **(unaudited)**	2025 *RMB'000* (unaudited)
REVENUE	*5*	**7,595,424**	6,440,951
Cost of sales		**(5,120,555)**	(4,268,750)
Gross profit		**2,474,869**	2,172,201
Other income and gains	*6*	**131,820**	105,153
Other expenses	*6*	**(123,830)**	(58,387)
Selling and distribution expenses		**(169,426)**	(142,944)
Administrative expenses		**(994,811)**	(848,836)
Research and development costs		**(295,830)**	(250,460)
Impairment losses on financial and contract assets		**(16,970)**	(37,143)
Finance costs		**(99,968)**	(94,171)
Share of gains/(losses) of associates		**20,324**	(32,657)
Profit before tax	*7*	**926,178**	812,756
Income tax expense	*8*	**(214,475)**	(160,126)
Profit for the period		**711,703**	652,630
Attributable to:			
Owners of the parent		**750,194**	701,396
Non-controlling interests		**(38,491)**	(48,766)
		711,703	652,630
EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT		**RMB**	RMB
Basic			
For profit for the period	*10*	**0.4138**	0.3984
Diluted			
For profit for the period	*10*	**0.4113**	0.3978

INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

FOR THE SIX MONTHS ENDED JUNE 30, 2026

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
	(unaudited)	(unaudited)
Profit for the period	**711,703**	652,630
OTHER COMPREHENSIVE (LOSS)/INCOME		
Other comprehensive (loss)/income that may be reclassified to profit or loss in subsequent periods:		
Exchange differences on translation of foreign operations	**(182,863)**	268,923
Other comprehensive loss attributable to profit or loss under the equity method	**(87)**	–
Fair value (losses)/gains on:		
Hedging instruments designated in cash flow hedges	**(6,982)**	21,679
Income tax effect	**1,105**	(3,252)
Net other comprehensive (loss)/income that may be reclassified to profit or loss in subsequent periods	**(188,827)**	287,350
Other comprehensive (loss)/income for the period, net of tax	**(188,827)**	287,350
Total comprehensive income for the period	**522,876**	939,980
Attributable to:		
Owners of the parent	**571,677**	977,454
Non-controlling interests	**(48,801)**	(37,474)
	522,876	939,980

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AS AT JUNE 30, 2026

	Notes	**June 30, 2026** ***RMB'000*** **(unaudited)**	December 31, 2025 *RMB'000* (audited)
NON-CURRENT ASSETS			
Property, plant and equipment		**12,654,577**	12,124,897
Right-of-use assets		**929,579**	852,287
Goodwill		**3,507,639**	3,585,974
Other intangible assets		**620,757**	634,539
Investments in associates		**790,785**	639,861
Equity investments at fair value through profit or loss		**697,466**	518,451
Biological assets		**172,625**	172,574
Deferred tax assets		**268,762**	262,907
Other non-current assets		**434,248**	524,126
Total non-current assets		**20,076,438**	19,315,616
CURRENT ASSETS			
Inventories		**803,299**	641,158
Contract costs		**713,333**	422,816
Trade and bills receivable	*11*	**2,864,935**	2,721,913
Contract assets		**524,562**	465,832
Biological assets		**418,145**	408,331
Prepayments, other receivables and other assets		**1,091,829**	1,364,012
Financial assets at fair value through profit or loss		**876,199**	714,073
Derivative financial instruments		**1,449**	22,550
Pledged deposits		**118,555**	174,792
Cash and cash equivalents		**1,457,570**	842,690
Total current assets		**8,869,876**	7,778,167
CURRENT LIABILITIES			
Interest-bearing bank borrowings		**4,553,914**	4,766,489
Trade payables	*12*	**761,255**	606,590
Other payables and accruals		**2,028,015**	1,774,415
Derivative financial instruments		**4,668**	–
Contract liabilities		**1,168,125**	960,613
Lease liabilities		**126,676**	122,698
Tax payable		**79,826**	133,198
Total current liabilities		**8,722,479**	8,364,003
NET CURRENT ASSETS		**147,397**	(585,836)
TOTAL ASSETS LESS CURRENT LIABILITIES		**20,223,835**	18,729,780

	Notes	**June 30, 2026** ***RMB'000*** **(unaudited)**	December 31, 2025 *RMB'000* (audited)
NON-CURRENT LIABILITIES			
Interest-bearing bank borrowings		**1,920,499**	1,771,806
Deferred tax liabilities		**453,664**	397,151
Deferred income		**446,167**	442,865
Lease liabilities		**352,713**	379,423
Total non-current liabilities		**3,173,043**	2,991,245
NET ASSETS		**17,050,792**	15,738,535
EQUITY			
Share capital	*13*	**1,837,284**	1,778,843
Treasury shares		**(227,552)**	(304,892)
Reserves		**14,739,042**	13,590,208
Equity attributable to owners of the parent		**16,348,774**	15,064,159
Non-controlling interests		**702,018**	674,376
Total equity		**17,050,792**	15,738,535

1. GENERAL INFORMATION

Pharmaron Beijing Co., Ltd. was incorporated and registered in the People's Republic of China ("PRC") on July 1, 2004. With the approval of the China Securities Regulatory Commission, the Company completed its initial public offering and was listed on the Shenzhen Stock Exchange (stock code: 300759.SZ) on January 28, 2019. On November 28, 2019, the Company's shares were listed on the Main Board of the Stock Exchange of Hong Kong Limited (the "Stock Exchange") (stock code: 3759.HK). The address of the registered office is 8th Floor, Block 1, 6 Taihe Road, Beijing Economic Technological Development Area, Beijing, China.

The Company is a leading fully-integrated pharmaceutical R&D service platform with global operations that accelerate drug innovation for its customers. The principal activity of the Company and its subsidiaries (together, the "Group") is to provide contract research, development and manufacturing services for innovative pharmaceutical products throughout the research and development cycle and the services are organised in three major categories: laboratory services, CDMO services, and clinical development services.

2. BASIS OF PREPARATION

The interim condensed consolidated financial information for the six months ended June 30, 2026 has been prepared in accordance with International Accounting Standard ("IAS") 34 Interim Financial Reporting. The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual financial statements for the year ended December 31, 2025 which have been prepared in accordance with International Financial Reporting Standards (IFRSs).

The interim condensed consolidated financial information has been prepared under the historical cost convention, except for biological assets which are measured at fair value less costs to sell, equity investments at fair value through profit or loss, derivative financial instruments and financial assets and financial liabilities at fair value through profit or loss which have been measured at fair value. The interim condensed consolidated financial information is presented in Renminbi ("RMB") and all values are rounded to the nearest thousand except when otherwise indicated.

3. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group's annual consolidated financial statements for the year ended 31 December 2025, except for the adoption of the following amended IFRS Accounting Standards for the first time for the current period's financial information.

Amendments to IFRS 9 and IFRS 7	Amendments to the Classification and Measurement
Amendments to IFRS 9 and IFRS 7	Contracts Referencing Nature-dependent Electricity
Annual Improvements to IFRS Accounting Standards – Volume 11	Amendments to IFRS 1, IFRS 7, IFRS 9, IFRS 10 and IAS 7

The nature and impact of the revised IFRSs are described below:

Amendments to IFRS 9 and IFRS 7 Amendments to the Classification and Measurement of Financial Instruments clarify that a financial asset is derecognised when the entity's rights to the contractual cash flows expire or are transferred, while a financial liability is derecognised on the settlement date. The amendments introduce an accounting policy option to derecognise a financial liability that is settled through an electronic payment system before the settlement date if specified criteria are met. The amendments clarify how to assess the contractual cash flow characteristics of financial assets with environmental, social and governance and other similar contingent features. Moreover, the amendments clarify the requirements for classifying financial assets with non-recourse features and contractually linked instruments. The amendments also include additional disclosures for investments in equity instruments designated at fair value through other comprehensive income and financial instruments with contingent features. Since the Group's accounting policy for the derecognition of financial assets and liabilities in prior years aligned with the amendments and the Group did not have the financial assets that were addressed by the amendments, the amendments did not have any impact on the interim condensed consolidated financial information. The Group will provide additional disclosures for its equity investments designated at fair value through other comprehensive income in the Group's consolidated financial statements for the year ending 31 December 2026.

Amendments to IFRS 9 and IFRS 7 Contracts Referencing Nature-dependent Electricity clarify the application of the "own-use" requirements for in-scope contracts and amend the designation requirements for a hedged item in a cash flow hedging relationship for in-scope contracts. The amendments also include additional disclosures that enable users of financial statements to understand the effects these contracts have on an entity's financial performance and future cash flows. As the Group did not have any contracts that are in the scope of the amendments, the amendments did not have any impact on the interim condensed consolidated financial information.

Annual Improvements to IFRS Accounting Standards – Volume 11 set out narrow scope amendments to IFRS 1, IFRS 7 (and the accompanying Guidance on implementing IFRS 7), IFRS 9, IFRS 10 and IAS 7. The amendments include clarifications, simplifications, corrections or changes to improve consistency in the corresponding IFRS Accounting Standards. The amendments did not have any impact on the interim condensed consolidated financial information.

4. OPERATING SEGMENT INFORMATION

In response to the Group's business development and management needs, the Group has reorganised its business units into laboratory services, CDMO services, clinical development services and other segments based on their services. This change only affects the presentation of segment reporting and has no impact on financial statement data. Prior year segment disclosures have been re-presented to conform with the current year's presentation. The four reportable business segments are as below:

- The laboratory services segment includes laboratory chemistry and bioscience services, covering the synthesis and preparation, *in vitro* biology, *in vivo* pharmacology, DMPK and safety assessment for innovative drug projects across diverse molecular modalities, including small molecule drugs, biologics, oligonucleotides, peptides, antibodies, bioconjugates (ADC and XDC) and CGT products, etc.;

- The CDMO services segment includes API process development and manufacturing, materials science/ pre-formulation, formulation development and manufacturing, and analytical development services, covering a broad range of products including small molecules, biologics, oligonucleotides, peptides, bioconjugates (including ADC and XDC), and gene therapy products;

- The clinical development services segment includes overseas clinical development services (including radiolabelled science services and early-stage clinical trial services) and domestic clinical development services (including clinical research services and site management services);

- The "Others" segment.

Segment revenue and results

The following is an analysis of the Group's revenue and results by reportable segments.

Six months ended June 30, 2026 (unaudited)	**Laboratory services** *RMB'000*	**CDMO services** *RMB'000*	**Clinical development services** *RMB'000*	**Others** *RMB'000*	**Total** *RMB'000*
Segment revenue	**4,633,511**	**1,884,103**	**1,068,521**	**9,289**	**7,595,424**
Segment results	**1,887,893**	**481,667**	**104,344**	**965**	**2,474,869**
Unallocated amount:					
Other income and gains					**131,820**
Other expenses					**(123,830)**
Selling and distribution expenses					**(169,426)**
Administrative expenses					**(994,811)**
Research and development costs					**(295,830)**
Impairment losses on financial and contract assets					**(16,970)**
Finance costs					**(99,968)**
Share of gains of associates					**20,324**
Group's profit before tax					**926,178**

Six months ended June 30, 2025 (unaudited)	Laboratory services *RMB'000*	CDMO services *RMB'000*	Clinical development services *RMB'000*	Others *RMB'000*	Total *RMB'000*
Segment revenue	4,074,627	1,419,018	939,327	7,979	6,440,951
Segment results	1,727,479	324,509	115,767	4,446	2,172,201
Unallocated amount:					
Other income and gains					105,153
Other expenses					(58,387)
Selling and distribution expenses					(142,944)
Administrative expenses					(848,836)
Research and development costs					(250,460)
Impairment losses on financial and contract assets					(37,143)
Finance costs					(94,171)
Share of losses of associates					(32,657)
Group's profit before tax					812,756

Management monitors the results of the Group's business segments separately for the purpose of making decisions about resources allocation and performance assessment. No analysis of segment asset and liability is presented as the management does not regularly review such information for the purposes of resources allocation and performance assessment. Therefore, only segment revenue and segment results are presented.

Geographical information

(a) Revenue from external customers

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
	(unaudited)	(unaudited)
North America	**4,675,209**	4,072,640
Chinese Mainland	**1,381,084**	973,047
Europe	**1,307,854**	1,234,167
Asia (except Chinese Mainland)	**202,421**	135,344
Others	**28,856**	25,753
Total	**7,595,424**	6,440,951

The revenue information above is based on the locations of the customers.

(b) Non-current assets

	June 30, 2026 ***RMB'000*** **(unaudited)**	December 31, 2025 *RMB'000* (audited)
Chinese Mainland	**14,453,839**	13,597,240
Europe	**2,625,536**	2,830,317
North America	**1,886,256**	1,982,220
Others	**144,579**	124,481
Total	**19,110,210**	18,534,258

The non-current assets information above is based on the locations of the assets and excludes equity investments at fair value through profit or loss and deferred tax assets.

5. REVENUE

An analysis of revenue is as follows:

	Six months ended June 30,	
	2026 ***RMB'000*** **(unaudited)**	2025 *RMB'000* (unaudited)
Revenue from contracts with customers	**7,595,424**	6,440,951
Total	**7,595,424**	6,440,951

Revenue from contracts with customers

(a) Disaggregated revenue information

Segments	**Six months ended June 30,**	
	2026 ***RMB'000*** **(unaudited)**	2025 *RMB'000* (unaudited)
Type of services		
Laboratory services	**4,633,511**	4,074,627
CDMO services	**1,884,103**	1,419,018
Clinical development services	**1,068,521**	939,327
Others	**9,289**	7,979
Total	**7,595,424**	6,440,951
Timing of revenue recognition		
Services transferred at a point of time	**4,074,120**	3,434,909
Services transferred over time	**3,521,304**	3,006,042
Total	**7,595,424**	6,440,951

(b) Performance obligations

The Group has different contractual arrangements with different customers under two different charge methods: Full-Time-Equivalent ("FTE") or Fee-For-Service ("FFS") model.

For all services under the FTE model, revenue is recognised over time at the amount to which the Group has the right to invoice for services performed. Therefore, under practical expedients allowed by IFRS 15, the Group does not disclose the value of unsatisfied performance obligations under the FTE model.

Similarly, for certain services under the FFS model, revenue is recognised over time and contracts are generally within an original expected length of one year or less. Therefore, the practical expedients are also applied.

6. OTHER INCOME AND GAINS AND OTHER EXPENSES

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
	(unaudited)	(unaudited)
Other income		
Interest income	**23,011**	17,462
Government grants and subsidies related to		
– Assets	**13,898**	14,369
– Income	**26,955**	23,605
Subtotal	**63,864**	55,436
Other gains		
Gains on fair value change of biological assets	**9,948**	–
Gains on disposal of property, plant and equipment	**601**	–
Gains on equity investment at fair value through profit or loss	**49,228**	33,048
Gains on financial assets at fair value through profit or loss	**1,876**	16,134
Gains on derivative financial instruments	**879**	–
Gains on termination of lease contracts	**4,693**	26
Others	**731**	509
Subtotal	**67,956**	49,717
Total	**131,820**	105,153
Other expenses		
Foreign exchange loss, net	**(116,895)**	(31,972)
Losses on disposal of biological assets	**(2,952)**	(8,184)
Losses on disposal of property, plant and equipment	**–**	(3,388)
Losses on derivative financial instruments	**–**	(28)
Losses on fair value change of biological assets	**–**	(13,277)
Others	**(3,983)**	(1,538)
Total	**(123,830)**	(58,387)

7. PROFIT BEFORE TAX

The Group's profit before tax is arrived at after charging/(crediting):

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
	(unaudited)	(unaudited)
Depreciation of property, plant and equipment	**598,248**	503,117
Depreciation of right-of-use assets	**78,392**	82,101
Amortization of other intangible assets	**45,756**	24,208
Staff costs* (including directors' and chief executive's remuneration):		
Salaries and other benefits	**2,718,922**	2,336,016
Pension scheme contribution, social welfare and other welfare**	**857,489**	757,673
Share-based compensation expenses	**43,067**	29,459
Gains on financial assets at fair value through profit or loss	**(1,876)**	(16,134)
Gains on equity investment at fair value through profit or loss	**(49,228)**	(33,048)
(Gains)/losses on fair value change of biological assets	**(9,948)**	13,277
(Gains)/losses on derivative financial instruments	**(879)**	28
Losses on disposal of biological assets	**2,952**	8,184
Impairment losses on inventories, net of reversal	**1,303**	263
Impairment losses on financial and contract assets, net of reversal	**16,970**	37,143
Foreign exchange losses, net	**116,895**	31,972
Auditor's remuneration	**2,425**	2,425

* The staff costs for the period are included in "Cost of sales", "Administrative expenses", "Selling and distribution expenses" and "Research and development costs" in the interim condensed consolidated statement of profit or loss.

** There are no forfeited contributions that may be used by the Group as the employer to reduce the existing level of contributions.

8. INCOME TAX EXPENSE

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
	(unaudited)	(unaudited)
Current tax	**163,437**	177,788
Deferred tax	**51,038**	(17,662)
Total	**214,475**	160,126

9. DIVIDENDS

On June 12, 2026, the Company's shareholders approved the 2025 Profit Distribution at the annual general meeting as a final dividend of RMB0.2 (inclusive of tax) per share in respect of the year ended December 31, 2025 was declared to both holders of A Shares and H Shares and aggregate dividend amounted to RMB364,962,000 (inclusive of tax), excluding the dividend amount in the trust account relating to the First H Share Award and Trust Scheme. As of the date of this announcement, all dividends have been paid.

The directors of the Company have determined that no dividend will be proposed or declared in respect of the current interim period (Six months ended June 30, 2025: Nil).

10. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculations of basic and diluted earnings per share are based on:

	Six months ended June 30,	
	2026	2025
	RMB'000	*RMB'000*
	(unaudited)	(unaudited)
Earnings:		
Profit attributable to ordinary equity holders of the parent	**750,194**	701,396

	Six months ended June 30,	
	2026	2025
	(unaudited)	(unaudited)
Number of shares ('000):		
Weighted average number of ordinary shares in issue during the period, used in the basic earnings per share calculation	**1,812,730**	1,760,452
Effect of diluted potential ordinary shares:		
Effect of restricted share units and share awards issued by the Company	**11,224**	2,937
Weighted average number of ordinary shares in issue during the period, used in the diluted earnings per share calculation	**1,823,954**	1,763,389

11. TRADE AND BILLS RECEIVABLE

An ageing analysis of the trade and bills receivables as at the end of the reporting period, based on the invoice date and net of loss allowance, is as follows:

	June 30,	December 31,
	2026	2025
	RMB'000	*RMB'000*
	(unaudited)	(audited)
Within 1 year	**2,787,769**	2,651,564
1 year to 2 years	**77,166**	70,349
Total	**2,864,935**	2,721,913

Included in trade receivables are amounts due from related parties of RMB86,347,000 as at June 30, 2026 (December 31, 2025: RMB79,643,000) which are repayable on credit terms similar to those offered to the major customers of the Group.

12. TRADE PAYABLES

Trade payables are non-interest-bearing and normally settled on terms of one to three months.

An ageing analysis of the trade payables as at the end of the Reporting Period, based on the invoice date, is as follows:

	June 30, 2026 ***RMB'000*** **(unaudited)**	December 31, 2025 *RMB'000* (audited)
Within 1 year	**754,693**	599,085
Over 1 year	**6,562**	7,505
Total	**761,255**	606,590

The amount of trade payables due to a related party was RMB22,000 as at June 30, 2026 (December 31, 2025: RMB26,000).

13. SHARE CAPITAL

	June 30, 2026 ***RMB'000*** **(unaudited)**	December 31, 2025 *RMB'000* (audited)
Issued and fully paid:	**1,837,284**	1,778,843

A summary of movements in the Company's share capital is as follows:

	Number of shares in issue	**Share capital** *RMB'000*
At 31 December 2025 and 1 January 2026	1,778,842,866	1,778,843
Placing of new H shares	58,440,762	58,441
At June 30, 2026	1,837,283,628	1,837,284

On January 22, 2026, the Company successfully placed an aggregate of 58,440,762 new H Shares to no less than six independent placees at the price of HK$22.82 per H Share.

MANAGEMENT DISCUSSION AND ANALYSIS

A. Business Review

1. Principal Business

The Company is a leading fully-integrated pharmaceutical R&D services platform with global operations to accelerate drug innovation for its customers, providing fully-integrated drug research, development and manufacturing services throughout the research and development cycle. The Company has 28 R&D centers and manufacturing facilities across China, the U.K., the U.S. and Singapore, and keeps strengthening the integration of its service offerings both vertically and horizontally, continuously investing in building new service capabilities and improving management efficiency to meet the needs of the market and customers. Vertically, the Company is strengthening the seamless integration of the same discipline across different pharmaceutical R&D stages. Horizontally, the Company is strengthening the integration of different disciplines at the same pharmaceutical R&D stages, improving the science and technology of each discipline, expanding the service offerings, and promoting interdisciplinary collaborations. The Company has built a fully-integrated service platform for small molecule drugs, biologics and CGT products, and is committed to becoming a global leader in pharmaceutical R&D services across multiple therapeutic modalities. In addition, the Company will further develop its global footprints to provide customers with interdisciplinary and global service solutions, making full use of the Company's global scientific research talent network and meeting customers' regional strategic needs.

In recent years, the proportion of new drug modalities and hybrid-modalities, including oligonucleotides, peptides, and bioconjugates, in both global and Chinese innovative drug pipelines has surged, emerging as a key growth driver of the industry. To better capitalize on this trend, the Company will fully leverage the comprehensive strengths of its "end-to-end, fully integrated and multiple modalities capable" service platform to foster cross-business synergy, accelerate project delivery, and respond more effectively to customer needs. Accordingly, effective from the second quarter of 2026, the Company has consolidated its operations into three major platforms – Laboratory Services, CDMO Services, and Clinical Development Services – covering the following service offerings:

(1) Laboratory services

Laboratory services include laboratory chemistry and bioscience services, covering multiple drug modalities, such as small molecule drugs, biologics, oligonucleotides, peptides, antibodies, bioconjugates (ADC and XDC) and CGT products.

Laboratory chemistry is the root of our business, making it the core in the development of the Company. Laboratory chemistry services include medicinal chemistry, synthetic chemistry, chemistry for new modalities, analytical and purification chemistry, computer-aided drug design (CADD), and early-stage process chemistry. Laboratory chemistry provides customers with chemistry services such as design and synthesis of compound library, discovery of hit and lead compounds, design and/or synthesis and optimization of lead compounds, synthesis of new modalities (nucleosides/nucleotides, lipids, saccharides, peptides, and conjugates), and chiral and non-chiral separation and purification.

Bioscience services include laboratory protein production and characterization, structural biology, *in vitro* and *in vivo* DMPK/ADME, *in vitro* biology and *in vivo* pharmacology, safety assessment and bioanalytical services. Bioscience services provide customers with drug discovery services such as target validation, structural analysis, structure activity relationship studies, candidate compound identification, and druggability studies.

(2) CDMO services

CDMO services include API process development and manufacturing, material science/pre-formulation, formulation development and manufacturing, and analytical development services, covering a broad range of products including small molecules, biologics, oligonucleotides, peptides, bioconjugates (including ADC and XDC), and gene therapy products.

Small molecule services include process development and cGMP manufacturing of APIs and drug products from pilot to commercial production. The process development and manufacturing team provides such services as discovery and development of efficient and green synthetic routes, optimization of existing synthetic routes, and process scale-up to support preclinical and clinical development, as well as commercial API manufacturing; the material science/ pre-formulation team provides services for crystal screening, process development, and early formulation development; the formulation development team designs, modifies, and prepares oral formulations to satisfy preclinical, clinical, and commercial needs; and the analytical development team provides comprehensive analytical support for process development and manufacturing of APIs and pharmaceutical products. The cGMP API and drug product manufacturing facilities of the Company are qualified to manufacture products to support clinical trials in global markets, including the U.S., China and the EU. Our quality assurance system follows the guidelines of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH Guidelines) and supports the development and manufacture of APIs and pharmaceuticals meeting the regulatory requirements of FDA, NMPA and EMA, and can also support the preparation of complete regulatory data packages and documentation for regulatory filings and cGMP audits in U.S., EU, and Asia.

Biologics CDMO services include cell line development, upstream and downstream process development, formulation development and fill-and-finish process development, bioconjugation, supported by analytics with method development. Regarding manufacturing capabilities, the Company provides drug substance and product manufacturing services armed with 200L to 2,000L production capacity to support projects from pilot to commercial stage production. In addition, it also provides integrated ADC manufacturing services for early-stage clinical trial supplies.

Gene therapy CDMO services include plasmid synthesis encoding therapeutic genes, cell line development, cell bank establishment, plasmid and cell production process development, formulation process development, manufacturing of products, analytical method development and validation, product-related impurities identification and analysis, stability evaluation, product analysis and GMP batch release, covering the entire gene therapy CDMO process. The facility has been licensed by MHRA, the U.K. pharmaceutical administration authority, for the manufacture of biologics and CGT products.

(3) Clinical development services

Clinical development services include overseas and domestic clinical development services.

The overseas clinical development services include radio-labelled science services and early-stage clinical trial services. The radio-labelled science services of the Company help customers synthesize ^{14}C and tritium ^{3}H radio-labelled compounds and use for DMPK/ADME studies of various compounds in human, so as to accelerate their clinical development process. Through the independent early clinical R&D center with 96 beds in Maryland, U.S., the Company provides customers with clinical research services including comprehensive FIH studies, vaccine development/infectious challenge studies, comprehensive ^{14}C drug absorption, distribution and excretion trial, TQT/cardiac safety, and cross-ethnic bridging studies. The Company strengthened its clinical operations, biostatistics, pharmacovigilance, and FDA regulatory submission services in the U.S. These efforts will better assist Chinese customers in developing their products overseas and overseas customers in developing their products in China.

Domestic clinical development services include clinical research services and site management services, covering different service needs of clinical research. Among which, clinical research services mainly include: regulatory affairs and product registration, medical affairs, medical monitoring, clinical operations, data management and biostatistics, bioanalysis, pharmacovigilance, quantitative pharmacology, etc.; site management services include CRC services, hospital research and selection, SSU (Study Start Up) rapid start-up, healthy and patient volunteer recruitment and management, quality assurance and its training, post-marketing studies, etc. The Company comprehensively promoted the application of digital technologies and AI tools across multiple business units, including site management, clinical operations, regulatory affairs, medical affairs, data management, biostatistics, pharmacovigilance, medical device R&D, patient management and real-world study, to enhance the quality and efficiency of its clinical services, as well as its digital products development and delivery capabilities.

The Company's bioanalytical platforms in China and U.S. are able to support the bioanalysis of clinical trials of small molecules and biologics around the world. In addition, with the collaboration among the domestic and overseas clinical development services and the preclinical service offerings, it allows the Company to simultaneously submit IND applications for customers' drug candidates to regulatory agencies in China, U.S. and EU.

B. Financial Review

1. Overall Operation Results

In the first half of 2026, the Company remained steadfast in implementing its core strategy of developing an "End-to-end, Fully-integrated, Globalized, and Multiple Modalities Capable" services platform with global footprints to further support its customers in improving the efficiency and flexibility of their pharmaceutical R&D and manufacturing needs, and its business has maintained a solid growth momentum. During the Reporting Period, the Company recognized revenue of RMB7,595.4 million, representing a year-on-year increase of 17.9%. The Company obtained the net profit attributable to owners of the parent of RMB750.2 million, representing a year-on-year increase of 7.0%. In the same period, its non-IFRSs adjusted net profit attributable to owners of the parent reached RMB909.0 million, representing a year-on-year increase of 20.3%.

The Company continued to adhere to the "Customer Centric" corporate philosophy, leveraging its end-to-end and fully-integrated services platform, adhering to the highest international quality standards, and the advantages of seamless collaborations among teams in China, the U.K. and the U.S., the Company has effectively met the diverse needs of global customers across different R&D stages. In terms of strategic customer development, the Company gained deeper insights into customer needs and achieved notable results, with particularly strong performance among large global pharmaceutical companies. Meanwhile, the Company continued to expand its customer base, empowering customers' innovative drug R&D projects with cutting-edge technologies. While maintaining its industry leadership in small molecule R&D services, the Company also achieved rapid development in new modality projects. For the China market, with the rapid globalization of China-originated innovative drugs, the Company actively implemented market strategies that are better tailored to the local landscape, and achieved rapid growth. In the first half of 2026, driven by the continued expansion of the Company's strategic customer portfolio and the progression of its CDMO project pipeline toward later stages, the Company's newly signed purchase orders increased by more than 30% year-on-year. According to new orders and business trends, the Company expects revenue to increase by 15% to 20% year-on-year in 2026.[1]

1 Such expectations are based on certain assumptions regarding the Company's business operations and on factors beyond the Company's control, and are subject to significant risks and uncertainties. As a result, actual results may differ materially from those anticipated.

As of the end of the Reporting Period, on a rolling twelve-month basis, the Company served over 3,400 global customers, with its customer coverage further expanding. During the Reporting Period, the Company added over 470 new customers, contributing revenue of RMB137.6 million, accounting for 1.8% of the Company's revenue. Its existing customers contributed revenue of RMB7,457.8 million, representing a year-on-year increase of 18.1%, accounting for 98.2% of the Company's revenue. During the Reporting Period, customers utilizing the continuous services of multiple business segments of the Company contributed revenue of RMB5,590.8 million, accounting for 73.6% of the Company's revenue. Categorized by customer types, during the Reporting Period, the revenue from the global top 20 pharmaceutical companies was RMB1,541.0 million, with a year-on-year increase of 32.0%, accounting for 20.3% of its total revenue; the revenue from other customers was RMB6,054.4 million, with a year-on-year increase of 14.8%, accounting for 79.7% of its total revenue. Categorized by regions where the customers are located, during the Reporting Period, the revenue from customers in North America was RMB4,675.2 million, with a year-on-year increase of 14.8%, accounting for 61.6% of its total revenue; the revenue from customers in EU (including the U.K.) was RMB1,307.9 million, with a year-on-year increase of 6.0%, accounting for 17.2% of its total revenue; the revenue from customers in China Mainland was RMB1,381.1 million, with a year-on-year increase of 41.9%, accounting for 18.2% of its total revenue; and the revenue from customers in other regions was RMB231.2 million, with a year-on-year increase of 43.6%, accounting for 3.0% of its total revenue.

The Company continued to bring in high-level domestic and overseas talents and enhance its global capabilities and capacities to support its growing business. As of June 30, 2026, the total number of employees reached 27,316, including 24,953 R&D, production technology and clinical services staff, accounting for 91.3% of the total number of employees in the Company. With the expansion of its global footprint, the Company owns 11 operating facilities and has more than 1,700 employees in the U.K. and the U.S.. In the first half of 2026, the delivered revenue of the overseas subsidiaries was RMB786.6 million, representing a year-on-year decrease of 1.9%, accounting for 10.4% of its total revenue.

The Company actively embraced technological development and transformation, committed to empowering its customers' R&D innovations through the application of cutting-edge technologies. During the Reporting Period, the Company continued to strengthen its laboratory service and CDMO service capabilities in new therapeutic modalities, including induced proximity therapeutics, peptides, oligonucleotides, bispecific and multispecific antibodies, bioconjugates, and cell and gene therapy products. The Company also enhanced the development of its New Approach Methodologies (NAM) technology platforms and further expanded AI and automation technology adoption across various business units. In July 2026, the Company collaborated with Logical Qubit, a superconducting quantum computing company, and Zhejiang University to jointly explore the application of quantum computing in drug discovery, aiming to advance computer-aided drug design and enhance R&D service efficiency. In August 2026, the Company entered into a strategic partnership with AI² Robotics, an AGI-native general-purpose robotics company, to jointly explore the development of innovative and intelligent laboratories. The partnership aims to integrate embodied intelligent robots into real-world R&D and manufacturing workflows to support the intelligent transformation of the life sciences industry.

In the first half of 2026, the Company continued to advance the development of its management systems in key areas including environmental management, labor and human rights, business ethics, and sustainable procurement. Through policy enhancement, indicator optimization, and strategy implementation, the Company further strengthened its ESG governance framework. In environmental management, the Company continued to strengthen environmental management systems across its sites and actively promoted third-party certifications. In line with its commitment to the Science Based Targets initiative (SBTi), the Company continued to advance greenhouse gas emissions accounting and the identification of decarbonization pathways, while promoting a green and low-carbon transition through renewable energy substitution, equipment upgrades and retrofits, application of low-carbon technologies, and collaborative emissions reduction across the supply chain. The Company continued to promote renewable electricity procurement and optimize its energy structure. In 2025, renewable electricity accounted for 42.0% of the Company's total electricity consumption. During the first half of 2026, the Company further increased its use of renewable electricity and targets 100% renewable electricity for the Group's operational electricity consumption by 2030. Meanwhile, the Company continued to improve energy efficiency, expand the use of renewable energy, and advance emissions reduction management in accordance with its science-based target pathway, while reaffirming its commitment to achieving net-zero emissions by 2050. During the Reporting Period, the Company further strengthened its capabilities in product carbon footprint (PCF) and life cycle assessment (LCA), and initiated life cycle carbon emissions assessments for key products. These efforts help identify environmental impacts and emissions reduction opportunities across the full product life cycle, providing a scientific basis to support customers' low-carbon transition needs and the Company's green innovation initiatives. In terms of management system development, the Company continued to incorporate key areas such as environmental management, occupational health and safety, animal welfare, information security, and data protection into its global management system framework. During the Reporting Period, AAALAC accreditation coverage across animal research sites increased from 67% to 89%. In the areas of information security, data protection, and responsible innovation, the Company continued to advance the development of its ISO 27001 management system and expects to achieve full certification coverage across all major operating sites in 2026. During the Reporting Period, the Company established an AI Strategy Committee to further strengthen AI-related governance and oversight. In sustainable procurement, the Company integrated requirements relating to environmental protection, labor and human rights, occupational health and safety, business ethics, information security, quality management, and compliance throughout the supplier management process. With reference to the principles of the Pharmaceutical Supply Chain Initiative (PSCI) and industry best practices, the Company continued to enhance its closed-loop supply chain ESG management mechanism. The Company also officially joined the PSCI Supplier Partnership, further integrating into the international responsible supply chain management system.

2. Operation results of each business segment[2]

(1) Laboratory services

During the Reporting Period, the laboratory services segment recognized revenue of RMB4,633.5 million, with a year-on-year growth of 13.7%; and a gross margin of 40.7% in the first half of 2026, with a decrease of 1.7 percentage points year-on-year, mainly resulted from the appreciation of RMB against the U.S. dollar during the Reporting Period. During the Reporting Period, the Company's newly signed purchase orders for laboratory services increased by more than 20% year-on-year. In the first half of 2026, the Company expanded its strategic customer base, achieved breakthrough progress in large-scale collaboration projects, and leveraged its expertise and technological capabilities to drive rapid growth in R&D services for new therapeutic modalities. During the Reporting Period, the proportion of bioscience services in laboratory services revenue exceeded 60%. As of June 30, 2026, the Company had 12,528 employees engaged in laboratory services, representing an increase of 432 employees as compared with the end of last year. The Company has over 7,200 laboratory chemists and technicians in laboratory chemistry services, being one of the world's leading groups in terms of size and expertise. The Company continued to contribute to global innovative drug R&D, provided customers with more flexible and comprehensive laboratory services through seamless collaborations among laboratory services teams in China, the U.K. and the U.S., meeting customers' diverse needs across different R&D stages, improving R&D efficiency, and helping customers rapidly advance R&D projects from preclinical R&D to clinical stage across multiple countries and regions. The Company's laboratory services team participated in 811 global innovative drug discovery projects during the Reporting Period.

2 Effective from the second quarter of 2026, the Company adjusted its financial reporting segments by consolidating its original Laboratory Services, CMC (Small Molecule CDMO) Services, Clinical Development Services, and Biologics and CGT Services segments into Laboratory Services, CDMO Services and Clinical Development services, and retrospectively restated the comparative period data. Accordingly, the revenue, gross profit margin and workforce movement data disclosed in this section are presented on a basis comparable with the retrospectively restated figures.

During the Reporting Period, the Company's bioscience team continued to enhance its service capabilities. Through its in-depth understanding and efficient management of service projects, the Company achieved seamless cross-platform collaborations, providing customers with multi-dimensional experimental data to more accurately evaluate the efficacy and safety of drug candidates. The Company further integrated AI and automation technologies into core R&D processes, including automated data collection and processing for cryo-electron microscopy (Cryo-EM), AI-driven enzyme and protein design, and continuous optimization of the drug DMTA (Design, Make, Test, Analyse) cycle. These efforts accelerate the development of new assays and enable efficient responses to customer needs. In terms of cutting-edge technology deployment, the Company strengthened its capabilities in New Approach Methodologies (NAM), expanded its portfolio of organoid and organ-on-a-chip models, explored the application of virtual screening and modelling, and supported customers in optimizing analytical strategies and translational pathways from preclinical to clinical stages. In addition to its long-established expertise in small molecule services, the Company continued to strengthen its R&D service capabilities for new therapeutic modalities, including induced proximity therapeutics, peptides, oligonucleotides, antibodies, proteins, bioconjugates, and CGT products. From early-stage screening to IND filings, its end-to-end services provide customers with extensive, efficient, and reliable solutions.

Laboratory chemistry is the core driver of small molecule drug discovery services. The Company leveraged its years of accumulated expertise to continuously expand its service scope and enrich its service offerings. Building on this foundation, the Company continued to extend its laboratory chemistry services into complex modalities, including induced proximity therapeutics, peptides, oligonucleotides, bioconjugates, etc, and achieved rapid growth. During the Reporting Period, the Company continued to promote the application of AI technologies in laboratory chemistry and gradually developed a human-machine collaboration model under which AI generates solution recommendations while chemists retain responsibility for critical scientific decision-making. Application scenarios include AI-assisted synthesis route design and optimization, AI-enabled high-throughput experimentation (HTE), AI-assisted reaction condition screening and problem analysis, and green synthesis route development to enhance chemical reaction success rates. It also explored the application of automation technologies in synthetic reactions, compound library generations, compound separations and purifications, aiming to deliver compounds with greater efficiency and reduced manual intervention, and achieved initial progress. Moving forward, the Company will continue to invest in AI and automation to further improve its productivity.

To meet the mid-to-long-term development needs, the Company continued to expand its capacity during the Reporting Period. Campus III in Beijing was gradually put into operation, while the construction of Campuses III and IV in Ningbo progressed steadily.

(2) CDMO Services

During the Reporting Period, the CDMO Services segment recognized revenue of RMB1,884.1 million, with a year-on-year growth of 32.8%; and a gross margin of 25.6%, with an increase of 2.7 percentage points year-on-year. The Company continued to make significant progress in the large-scale manufacturing for small molecule CDMO projects, contributing to rapid revenue growth and continuous improvement of the gross profit margin. During the Reporting Period, the Company's newly signed purchase orders for CDMO services increased by more than 50% year-on-year, driven by an expanding project pipeline and the continued progression of existing projects into later stages. As of June 30, 2026, the Company had 6,839 employees in CDMO services, representing an increase of 950 employees as compared with the end of last year. With the seamless integration of the Company's fully integrated R&D service platform and the coordination of different service segments, during the Reporting Period, approximately 85% of CDMO services revenue came from the Company's existing customers of drug discovery services.

In terms of Small Molecule CDMO services, the Company has a team of process development chemists with industry-leading scale and experience in both China and the U.K., providing customized services to global customers with state-of-the-art technologies. Its manufacturing facilities in China, the U.K. and the U.S. offer customers flexible, efficient and cost-effective integrated solutions from preclinical to commercial production, covering intermediates, APIs and formulations. During the Reporting Period, the Company's CDMO services pipeline reached 782 molecules or intermediates, including 45 projects in process validation and commercialization stages, 51 projects in Phase III clinical trials, 238 projects in Phase I-II clinical trials, and 448 projects in the preclinical stage. Its Small Molecule CDMO project pipeline continued to expand and progress toward later stages. During the Reporting Period, the Company signed a partnership agreement with a major multinational pharmaceutical company to provide commercial drug product manufacturing services for its first submitted oral, small molecule GLP-1 receptor agonist medicine. Its facility at Campus I in Ningbo successfully passed the first pre-approval inspection (PAI) for the Company's innovative drug API CDMO project for the China market, further demonstrating the Company's sound quality management system and commercial production capabilities.

In terms of biologic CDMO services, the Company continued to provide GMP production services to a global pharmaceutical company for an innovative bispecific antibody intended for use in clinical trials, and further expanded its biologic CDMO pipeline, including monoclonal antibodies, bispecific antibodies, multispecific antibodies, and fusion proteins. Its number of customers and projects continued to increase. During the Reporting Period, building upon its expertise in biologics production, linkers and small molecule synthesis, and bioconjugation capabilities, the Company continued to expand its bioconjugates CDMO business, made encouraging progress, and secured multiple integrated project orders.

In terms of gene therapy CDMO services, during the Reporting Period, the Company's laboratories and factories in Liverpool, the U.K. supported 15 projects across different service categories and R&D stages, including 9 Phase I/II clinical projects and 6 preclinical projects. Building on this foundation, the Company further expanded its services to other therapeutic modalities, including protein production services, thereby further diversifying its project portfolio.

During the Reporting Period, the Company continued to strengthen its CDMO capabilities and capacities. It expanded the application of technologies including flow chemistry, biocatalysis, electrochemistry, and photochemistry, and high-throughput screening across various stages of R&D and manufacturing, achieving notable progress. As the demand for late-stage clinical and commercial-stage Small Molecule CDMO projects continues to grow, the Company is accelerating the construction of Phase II of Campus I in Shaoxing, and plans to build additional Small Molecule CDMO capacity in Shaoxing and Hangzhou to meet the rapidly growing customer needs. In complex peptide CDMO services, the Company is further expanding its capacities, offering customers more comprehensive services. Beyond its existing peptide GMP pilot plant, a new, larger-scale solid-phase synthesis facility for peptide APIs is expected to be completed in 2026. Meanwhile, the Company is also actively exploring advanced liquid-phase peptide synthesis technologies to further enhance its service offerings. In bioconjugate CDMO services, the Company will continue to advance the construction of bioconjugation facilities for mid-to-late-stage clinical trial materials and commercial production, providing customers with integrated services from R&D to commercial manufacturing.

(3) Clinical Development Services

During the Reporting Period, the clinical development services segment recognized revenue of RMB1,068.5 million, with a year-on-year growth of 13.8%; and a gross margin of 9.8%, with a decrease of 2.5 percentage points year-on-year. The Company continued to enhance its service efficiency through refined operations and the application of digital and intelligent tools. Leveraging dual regulatory filing services in China and the U.S., the Company expanded its presence in the U.S. market. During the Reporting Period, the Company's newly signed purchase orders for clinical development services increased by more than 30% year-on-year.

During the Reporting Period, the Company's clinical CRO team provided services to 1,357 ongoing projects, including 132 projects in Phase III clinical trials, 589 projects in Phase I/II clinical trials, and 636 other clinical trial projects (including Phase IV clinical trials, investigator-initiated trials and real-world studies). The Company's clinical research site management services (SMO) team provided services to over 2,200 ongoing projects. Its CRC team covered over 700 hospitals and clinical trial centers in over 150 cities in China for clinical research site management services.

As of June 30, 2026, the Company had 5,586 employees in clinical development services, representing an increase of 697 employees compared to the end of last year, including more than 400 overseas employees. Pharmaron Clinical has established an integrated clinical trial service platform in China, an independent early clinical R&D center with 96 beds in Maryland, the U.S., and an integrated platform of "radioisotope compound synthesis-clinical-analysis" in the U.K. and the U.S.. Pharmaron Clinical's domestic and overseas teams work closely to help overseas customers develop their products in China and help Chinese customers develop their products overseas.

Pharmaron Clinical is committed to building a digital and intelligent clinical R&D service platform, providing customers with efficient and differentiated services. During the Reporting Period, the Company established the Clinical AI Innovation Center and continued to deepen the application of AI and digital tools in clinical development services. Leveraging its proprietary AI platform, the Company expanded the application of AI, automation and other technologies across business functions including pharmacovigilance, biostatistics, regulatory affairs, medical writing and data management. These initiatives reduced costs, improved efficiency, and enhanced the quality of services.

During the Reporting Period, the Company continued to strengthen its end-to-end healthcare service platform by promoting integration between its clinical and preclinical businesses and data and AI technologies. Leveraging its proprietary AI technology platform, the Company's controlling subsidiary Aistarfish Technology expanded its integrated in-hospital and out-of-hospital cancer patient management services, and continued to strengthen AI capabilities in patient management and RWS services. During the Reporting Period, multiple research findings were presented at leading domestic and international academic conferences, further enhancing its expertise in AI healthcare technology and academic influence. On the business front, Aistarfish Technology achieved meaningful scale in orders for real-world patient management and RWS services, and partnered with top-tier domestic hospitals for RWS collaborations. Additionally, through collaborations with the Company's clinical and preclinical business units, Aistarfish Technology is actively building high-quality real-world data and multi-omics cohorts for precise patient populations, aiming to enhance the efficiency of innovative drug R&D processes for the Company's customers and post-market research efforts.

3. Industry competition and development

The Company is engaged in pharmaceutical research, development and manufacturing services which provides fully integrated services to support our global customers' R&D for innovative pharmaceutical products, covering small molecule drugs, biologics and cell and gene therapy products. Its business is closely related to the development of the pharmaceutical industry and pharmaceutical R&D outsourcing market.

The long-term industry fundamentals for global and China pharmaceutical R&D and manufacturing remain intact, and the investment is expected to maintain steady growth. The pursuit of health and longevity is eternal. With the accelerated growth of the aging population globally, the expansion of the chronic disease patient population and the increase in the total investment in the medical and healthcare industry in various countries, the global and China pharmaceutical markets continue to develop, which in turn drives the continuous increase of the pharmaceutical R&D and manufacturing spending. The spending on pharmaceutical research, development and manufacturing is expected to maintain solid growth both globally and in China.

The pharmaceutical R&D and manufacturing outsourcing services market is expected to maintain a rapid growth, and the market share of the fully-integrated R&D services platform that serve global customers is expected to continue to increase. The innovative drug R&D industry features large investments, high risks and long R&D cycles, and the fully-integrated R&D services platform can help to improve the overall R&D efficiency of the customers by reducing costs and R&D risks. First of all, as a result of increasing R&D costs and patent cliffs, as well as the internal R&D talent and capacity limitations, large pharmaceutical companies gradually turn to pharmaceutical R&D and manufacturing outsourcing services with an aim to reduce their overall R&D costs and improve their R&D efficiency. It is expected that the large pharmaceutical companies will continue to increase the proportion of R&D outsourcing in the overall R&D investment. Secondly, small and midsized biotech companies have become an important driver of pharmaceutical innovation. These biotech companies generally have yet to establish comprehensive R&D and manufacturing capabilities and rely more on outsourcing services to advance their R&D projects. Thirdly, the fully-integrated R&D platform serving global customers is well positioned to meet the various needs of different customers, especially small and midsized biotech customers, across the entire pharmaceutical R&D process. Through seamless collaborations among each business segment, the fully-integrated service platform can help customers to further improve efficiencies, and is expected to continuously increase its market share.

4. Profit in the Reporting Period

The profit attributable to owners of the parent in the Reporting Period was approximately RMB750.2 million, increased by 7.0% as compared to approximately RMB701.4 million for the six months ended June 30, 2025.

5. Basic and Diluted Earnings Per Share

The basic earnings per share was RMB0.4138, increased by 3.9% as compared to RMB0.3984 for the six months ended June 30, 2025. The diluted earnings per share was RMB0.4113, increased by 3.4% as compared to RMB0.3978 for the six months ended June 30, 2025.

6. Non-IFRSs Adjusted Net Profit for the Period Attributable to Owners of the Parent

To supplement the financial statements prepared by us, we use non-IFRSs adjusted net profit attributable to owners of the parent as an additional financial measure. We define non-IFRSs adjusted net profit attributable to owners of the parent as net profit before certain expenses/(gains) as set out in the table below.

The Company believes that the consideration of the non-IFRSs adjusted net profit attributable to owners of the parent by eliminating the impact of certain incidental, non-cash or non-operating items is useful for better understanding and assessing underlying business performance and operating trends for the Company's management, shareholders and potential investors. The non-IFRSs adjusted net profit attributable to owners of the parent is not an alternative to (i) profit before tax or net profit (as determined in accordance with IFRSs) as a measure of our operating performance, (ii) cash flows from operating, investing and financing activities as a measure of our ability to satisfy our cash needs, or (iii) any other measures of performance or liquidity. In addition, the presentation of the non-IFRSs adjusted net profit attributable to owners of the parent is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with the IFRSs. Shareholders and potential investors should not view the non-IFRSs adjusted net profit attributable to owners of the parent on a stand-alone basis or as a substitute for results under the IFRSs, or as being comparable to results reported or forecasted by other companies.

	Six months ended June 30, 2026 ***RMB'000*** **(unaudited)**	Six months ended June 30, 2025 *RMB'000* (unaudited)
Profit attributable to owners of the parent	**750,194**	701,396
Add:		
Share-based compensation expenses	**37,482**	25,735
Foreign exchange related losses	**103,574**	22,755
Amortization of intangible assets from acquisitions	**14,496**	1,074
Realized and unrealized (gains)/losses from equity investments	**(30,784)**	4,741
One-off reorganization-related expenses	**34,051**	–
Non-IFRSs adjusted net profit attributable to owners of the parent	**909,013**	755,701

7. Cash Flows

During the Reporting Period, net cash flows generated from operating activities of the Group amounted to approximately RMB1,084.6 million, representing a decrease of approximately RMB323.6 million or 23.0% as compared to the six months ended June 30, 2025.

During the Reporting Period, net cash flows used in investing activities of the Group amounted to approximately RMB1,295.6 million, representing a decrease of approximately RMB441.7 million or 25.4% as compared to the six months ended June 30, 2025.

During the Reporting Period, net cash flows generated from financing activities of the Group amounted to approximately RMB864.5 million, representing an increase of RMB965.6 million or 955.7% as compared to the six months ended June 30, 2025. The increase was mainly due to the cash inflows from the placing of new H Shares during the Reporting Period.

8. Liquidity and Financial Resources

The Group has maintained a sound financial position during the Reporting Period. As at June 30, 2026, the Group's cash and cash equivalents amounted to approximately RMB1,457.6 million. During the Reporting Period, net cash flows generated from operating activities of the Group amounted to approximately RMB1,084.6 million.

The Group recorded total current assets of approximately RMB8,869.9 million as at June 30, 2026 (December 31, 2025: approximately RMB7,778.2 million) and total current liabilities of approximately RMB8,722.5 million as at June 30, 2026 (December 31, 2025: approximately RMB8,364.0 million). The current ratio (calculated by dividing the current assets by the current liabilities) of the Group was approximately 1.0 as at June 30, 2026 (December 31, 2025: approximately 0.9).

9. Borrowings and Gearing Ratio

As at June 30, 2026, the Group aggregated interest-bearing bank borrowings of RMB6,474.4 million. Among the total borrowings, RMB4,553.9 million will be due within one year and RMB1,920.5 million will be due after one year.

As at June 30, 2026, the Group's gearing ratio, calculated as total liabilities over total assets, was 41.1%, as compared with 41.9% as at December 31, 2025.

10. Pledge of Assets

As at June 30, 2026, the Group mortgaged property, plant and equipment with a net carrying amount of approximately RMB306.4 million (December 31, 2025: approximately RMB971.3 million); and the mortgaged right-of-use assets had a net carrying amount of approximately RMB66.7 million (December 31, 2025: approximately RMB122.7 million).

Those pledged assets above have been used to secure the Group's interest-bearing bank borrowings.

Besides, as at June 30, 2026, the Group pledged deposits of approximately RMB118.6 million (December 31, 2025: approximately RMB174.8 million) to issue letters of credit, environmental protection, construction guarantee and others.

11. Interim Dividend

The Board resolved not to declare any interim dividend for the six months ended June 30, 2026.

12. Contingent Liabilities

As at June 30, 2026, the Group did not have any material contingent liabilities.

13. Share Incentive Schemes

A Share Incentive Schemes

(1) 2021 A Share Incentive Scheme

On July 12, 2021, the Shareholders resolved to adopt the 2021 A Share Incentive Scheme, the assessment management measures for the implementation of the 2021 A Share Incentive Scheme and the authorization to the Board to handle matters pertaining to the 2021 A Share Incentive Scheme.

(i) Purpose of the 2021 A Share Incentive Scheme

In order to further perfect the Company's corporate governance structure, establish and improve the Company's long-term incentive mechanism, attract and retain the Company's core management, mid-level management, core technical personnel, basic-level management and technical personnel, fully mobilize their enthusiasm and creativity, effectively strengthen the cohesion of the core team and the competitiveness of the Company, align the interests of the shareholders, the Company and the core staff members, bring their attention to the long-term development of the Company and ensure that the Company's development strategy and business goals shall be realized, the 2021 A Share Incentive Scheme was approved by the general meeting.

(ii) Category of grantees and participants of the 2021 A Share Incentive Scheme

The total number of grantees who have been granted and who have taken up the relevant Restricted A Shares under the 2021 A Share Incentive Scheme is 204, including core management of the Company, mid-level managements and core technical personnel and basic-level management and technical personnel. All eligible participants must have an employment or labour relationship with the Company or its subsidiaries when a grant under the 2021 A Share Incentive Scheme is made and during the assessment period of the 2021 A Share Incentive Scheme.

None of the Directors, members of senior management, non-PRC employees, shareholders who individually or collectively hold more than 5% of the Shares of the Company, de facto controllers, or their respective spouses, parents or children, or any respective associates of the Directors, substantial shareholders has been the grantee of any awards granted pursuant to the 2021 A Share Incentive Scheme.

(iii) Maximum entitlement of each participant and maximum number of Restricted A Shares to be issued by the Company under the 2021 A Share Incentive Scheme

None of the grants under the 2021 A Share Incentive Scheme was subject to approval by the shareholders of the Company. The grants under the 2021 A Share Incentive Scheme would not result in the awards granted and to be granted to each individual grantee in the 12-month period up to and including the date of such grant in aggregate to exceed 1% of the relevant class of shares in issue (excluding treasury shares (as defined under the Listing Rules)).

Pursuant to the Management Measures and the 2021 A Share Incentive Scheme, the maximum number of Restricted A Shares to be issued by the Company was 1,161,300 A Shares (as adjusted after the implementation of the 2021 Capitalization of Reserve), and was further adjusted to 1,741,950 A Shares (as adjusted after the implementation of the 2022 Capitalization of Reserve), representing approximately 0.09% of the Company's total number of issued Shares as of June 30, 2026. The total number of Shares to be granted to any participants under all the fully effective share incentive schemes of the Company shall not exceed 1% of the total share capital of the Company.

(iv) Grant price and the basis of determining the grant price

The grant price of the Restricted A Shares under the 2021 A Share Incentive Scheme shall be RMB70.47 per A Share (subject to adjustment). Pursuant to the Shenzhen Listing Rules and the Management Measures, the pricing method for the Restricted A Shares under the 2021 A Share Incentive Scheme is independent pricing, and the share price is the 50% of average trading price of the Company's shares for 120 trading days prior to the date of the announcement of the 2021 A Share Incentive Scheme, which is RMB70.47 per share:

1. 50% of the average trading price of the Company's shares on the trading day immediately preceding the date of the announcement on the adoption of the 2021 A Share Incentive Scheme amongst other things, being RMB92.57 per A Share;

2. 50% of the average trading price of the Company's shares for the 20 trading days immediately preceding the date of the announcement on the adoption of the 2021 A Share Incentive Scheme amongst other things, being RMB89.86 per A Share;

3. 50% of the average trading price of the Company's shares for the 60 trading days immediately preceding the date of the announcement on the adoption of the 2021 A Share Incentive Scheme amongst other things, being RMB77.47 per A Share; and

4. 50% of any one of the average trading price of the Company's shares for the 120 trading days immediately preceding the date of the announcement on the adoption of the 2021 A Share Incentive Scheme amongst other things, being RMB70.47 per A Share.

The grant price was determined in accordance with the price references abovementioned. This was also determined with a view to stabilize talents and effectively incentivize employees under different cycles and business environments which may allow the Company to gain advantage in the competitive industry that it operates in. The Board has also taken into consideration the level of difficulty of the performance targets which eligible participants must achieve for the restricted A Share(s) to be vested, and considers that this is in balance with a discount in the grant price.

As a result of the implementation of the 2020 Profit Distribution and pursuant to the Management Measures and the 2021 A Share Incentive Scheme, on July 27, 2021, the Board resolved to adjust the grant price of Restricted A Shares granted under the 2021 A Share Incentive Scheme from RMB70.47 per A Share to RMB70.17 per A Share.

As a result of the implementation of the 2021 Profit Distribution Plan and pursuant to the Management Measures and the 2021 A Share Incentive Scheme, on July 28, 2022, the Board resolved to adjust the grant price of Restricted A Shares granted under the 2021 A Share Incentive Scheme from RMB70.17 per A Share to RMB46.48 per A Share.

As a result of the implementation of the 2022 Profit Distribution Plan and pursuant to the Management Measures and the 2021 A Share Incentive Scheme, on October 27, 2023, the Board resolved to adjust the grant price of Restricted A Shares granted under the 2021 A Share Incentive Scheme from RMB46.48 per A Share to RMB30.79 per A Share.

As a result of the implementation of the 2023 Profit Distribution and pursuant to the Management Measures and the 2021 A Share Incentive Scheme, on August 27, 2024, the Board resolved to adjust the grant price of Restricted A Shares granted under the 2021 A Share Incentive Scheme from RMB30.79 per A Share to RMB30.59 per A Share.

As a result of the implementation of the 2024 Profit Distribution and pursuant to the Management Measures and the 2021 A Share Incentive Scheme, on August 21, 2025, the Board has resolved to adjust the grant price of Restricted A Shares granted under the 2021 A Share Incentive Scheme from RMB30.59 per A Share to RMB30.39 per A Share.

(v) Granting of Restricted A Shares during the Reporting Period

No awards were granted under the 2021 A Share Incentive Scheme during the Reporting Period, and no further share incentives shall be available for grant under the 2021 A Share Incentive Scheme.

(vi) Vesting and Forfeiture of Restricted A Shares during the Reporting Period

In January 2026, the Company conducted the registration of vesting of Restricted A Shares. Restricted A Shares were vested to a total of 44 eligible employees, and the total number of Restricted A Shares vested was 81,643. The Restricted A Shares vested were circulated on January 29, 2026.

In the process of payment of funds and share registration, a total of 247,688 Restricted A Shares that could be vested to 133 eligible employees were forfeited in whole or in part due to personal reasons. Please refer to the overseas regulatory announcement of the Company dated January 27, 2026 for further details.

As at the date of this announcement, all awards granted under the 2021 A Share Incentive Scheme have been vested or cancelled/forfeited.

(vii) Particulars of movement of unvested awards during the Reporting Period

The granted Restricted A Shares shall be vested over a four-year period, with 25%, 25%, 25% and 25% of total shares vesting on the first trading date after each anniversary date after the vesting commencement date upon meeting certain performance conditions, and shall last until the last trading dates by the next anniversary date.

Set out below are details of the unvested awards and the movements of the number of granted awards under the 2021 A Share Incentive Scheme during the Reporting Period:

Category of grantee	Date of grant	Grant Price[1]	Number of unvested and not registered awards as at January 1, 2026	Number of awards vested on January 27, 2026[2]	Number of awards cancelled/ forfeited on January 27, 2026	Number of unvested and not registered awards as at June 30, 2026
Employees	July 27, 2021	RMB30.39	329,331	81,643	247,688	0

Note:

(1) The grant price was adjusted from RMB30.59 to RMB30.39 as a result of the implementation of the 2024 Profit Distribution. Please refer to section under "(1) 2021 A Share Incentive Scheme – (iv) Grant price and the basis of determining the grant price" above for further details. Employees shall pay for the grant price of the vested Restricted A Shares based on the amount vested at the time of each vesting.

(2) The weighted average closing price of the A Shares immediately before the date on which the awards were vested was RMB29.85.

(viii) Remaining validity period of the 2021 A Share Incentive Scheme

The 2021 A Share Incentive Scheme shall be valid until the date on which all Restricted A Shares available for issue under the 2021 A Share Incentive Scheme have been vested or forfeited, and such period shall not exceed 60 months from the grant date. Accordingly, the 2021 A Share Incentive Scheme expired on June 30, 2026.

(ix) Others

As at June 30, 2026, the number of unvested and not registered awards is nil.

(2) 2022 A Share Incentive Scheme

On May 31, 2022, the Shareholders resolved to adopt the 2022 A Share Incentive Scheme, the assessment management measures for the implementation of the 2022 A Share Incentive Scheme and the authorization to the Board to handle matters pertaining to the 2022 A Share Incentive Scheme.

(i) Purpose of the 2022 A Share Incentive Scheme

In order to further perfect the Company's corporate governance structure, establish and improve the Company's long-term incentive mechanism, attract and retain the Company's core management, mid-level management and core technical personnel, basic-level management and technical personnel, fully mobilize their enthusiasm and creativity, effectively strengthen the cohesion of the core team and the competitiveness of the Company, align the interests of the shareholders, the Company and the core staff members, bring their attention to the long-term development of the Company and ensure that the Company's development strategy and business goals shall be realized, the 2022 A Share Incentive Scheme was approved by Shareholders' meeting of the Company.

(ii) Category of grantees and participants of the 2022 A Share Incentive Scheme

The total number of the eligible participants for the grant proposed under the 2022 A Share Incentive Scheme shall be 379. All eligible participants must have an employment or labour relationship with the Company or its subsidiaries when a grant under the 2022 A Share Incentive Scheme is made and during the assessment period of the 2022 A Share Incentive Scheme.

None of the Directors, members of senior management, non-PRC employee, shareholders who individually or collectively hold more than 5% of the Shares of the Company, de facto controllers, or their respective spouses, parents or children, or the respective associates of the Directors, substantial shareholders has been the grantee of any awards granted pursuant to the 2022 A Share Incentive Scheme.

(iii) Maximum entitlement of each participant and maximum number of Restricted A Shares to be issued by the Company under the 2022 A Share Incentive Scheme

None of the grants under the 2022 A Share Incentive Scheme was subject to approval by the shareholders of the Company. The grants under the 2022 A Share Incentive Scheme would not result in the awards granted and to be granted to each individual grantee in the 12-month period up to and including the date of such grant in aggregate to exceed 1% of the relevant class of shares in issue (excluding treasury shares (as defined under the Listing Rules)).

Pursuant to the Management Measures and the 2022 A Share Incentive Scheme, the maximum number of Restricted A Shares to be issued by the Company was 2,203,200 A Shares (as adjusted after the implementation of the 2021 Capitalization of Reserve), and was further adjusted to 3,304,800 A Shares (as adjusted after the implementation of the 2022 Capitalization of Reserve), representing approximately 0.18% of the Company's total number of issued Shares as of June 30, 2026. The total number of Shares to be granted to any participants under all the fully effective share incentive schemes of the Company shall not exceed 1% of the total share capital of the Company.

(iv) Grant price and the basis of determining the grant price

The grant price of the Restricted A Shares under the 2022 A Share Incentive Scheme was RMB58.38 per A Share (subject to adjustment). Pursuant to the Shenzhen Listing Rules and the Management Measures, the grant price of the Restricted A Shares under the 2022 A Share Incentive Scheme shall be not less than the par value of the Shares, and in principle not less than the higher of:

1. 50% of the average trading price of the Company's A Shares for one trading day immediately preceding the date of the announcement with respect to the adoption of the 2022 A Share Incentive Scheme, being RMB58.38 per A Share; and

2. 50% of the average trading price of the Company's A Shares for the 20 trading days immediately preceding the date of the announcement with respect to the adoption of the 2022 A Share Incentive Scheme, being RMB55.06 per A Share.

The grant price was determined in accordance with the price references abovementioned. This was also determined with a view to stabilize talents and effectively incentivize employees under different cycles and business environments which may allow the Company to gain advantage in the competitive industry that it operates in. The Board has also taken into consideration the level of difficulty of the performance targets which participants must achieve for the restricted share(s) to be vested, and considers that this is in balance with a discount in the grant price.

As a result of the implementation of the 2021 Profit Distribution Plan, and pursuant to the Management Measures and the 2022 A Share Incentive Scheme, on July 28, 2022, the Board resolved to adjust the grant price of Restricted A Shares granted under the 2022 A Share Incentive Scheme from RMB58.38 per A Share to RMB38.62 per A Share.

As a result of the implementation of the 2022 Profit Distribution Plan, and pursuant to the Management Measures and the 2022 A Share Incentive Scheme, on October 27, 2023, the Board resolved to adjust the grant price of Restricted A Shares granted under the 2022 A Share Incentive Scheme from RMB38.62 per A Share to RMB25.55 per A Share.

As a result of the implementation of the 2023 Profit Distribution, and pursuant to the Management Measures and the 2022 A Share Incentive Scheme, on August 27, 2024, the Board resolved to adjust the grant price of Restricted A Shares granted under the 2022 A Share Incentive Scheme from RMB25.55 per A Share to RMB25.35 per A Share.

As a result of the implementation of the 2024 Profit Distribution, and pursuant to the Management Measures and the 2022 A Share Incentive Scheme, on August 21, 2025, the Board has resolved to adjust the grant price of Restricted A Shares granted under the 2022 A Share Incentive Scheme from RMB25.35 per A Share to RMB25.15 per A Share.

(v) Granting of Restricted A Shares during the Reporting Period

No awards were granted under the 2022 A Share Incentive Scheme during the Reporting Period, and no further share incentives shall be available for grant under the 2022 A Share Incentive Scheme.

(vi) Vesting and Forfeiture of Restricted A Shares during the Reporting Period

In January 2026, the Company conducted the registration of vesting of Restricted A Shares. Restricted A Shares were vested to a total of 276 eligible employees, and the total number of Restricted A Shares vested was 565,698. The Restricted A Shares vested were circulated on January 29, 2026.

In the process of payment of funds and share registration, a total of 116,068 Restricted A Shares that could be vested to 65 eligible employees were forfeited in whole or in part due to personal reasons. Please refer to the overseas regulatory announcement of the Company dated January 27, 2026 for further details.

(vii) Particulars of movement of unvested awards during the Reporting Period

The granted Restricted A Shares shall be vested over a four-year period, with 25%, 25%, 25% and 25% of total shares vesting on the first trading date after each anniversary date after the vesting commencement date upon meeting certain performance conditions, and shall last until the last trading dates by the next anniversary date.

Set out below are details of the unvested awards and the movements of the number of granted awards under the 2022 A Share Incentive Scheme during the Reporting Period:

Category of grantee	Date of grant	Grant Price[1]	Number of unvested and not registered awards as at January 1, 2026	Number of awards vested on January 27, 2026[2]	Number of awards cancelled/ forfeited on January 27, 2026	Number of unvested and not registered awards as at June 30, 2026
Employees	July 28, 2022	RMB25.15	1,363,918	565,698	116,068	682,152

Note:

(1) The grant price was adjusted from RMB25.35 to RMB25.15 as a result of the implementation of the 2024 Profit Distribution. Please refer to "(2) 2022 A Share Incentive Scheme – (iv) Grant price and the basis of determining the grant price" for further details. Employees shall pay for the subscription funds for the Restricted A Shares based on the grant price at the time of each vesting.

(2) The weighted average closing price of the A Shares immediately before the date on which the awards were vested was RMB29.85.

(viii) Remaining validity period of the 2022 A Share Incentive Scheme

The 2022 A Share Incentive Scheme shall be valid until the date on which all Restricted A Shares have been vested or forfeited under the 2022 A Share Incentive Scheme, and such period shall not exceed 60 months. As such, as of June 30, 2026, the remaining life of the 2022 A Share Incentive Scheme is 12 months.

(ix) Others

As at June 30, 2026, the number of unvested and not registered awards is 682,152.

(3) 2023 A Share Incentive Scheme

On June 21, 2023, the Shareholders resolved to adopt the 2023 A Share Incentive Scheme, the assessment management measures for the implementation of the 2023 A Share Incentive Scheme and the authorization to the Board to handle matters pertaining to the 2023 A Share Incentive Scheme during the annual general meeting of the Company.

(i) Purpose of the 2023 A Share Incentive Scheme

In order to further perfect the Company's corporate governance structure, establish and improve the Company's long-term incentive mechanism, attract and retain the Company's core management, mid-level management, core technical personnel, basic-level management and technical personnel, fully mobilize their enthusiasm and creativity, effectively strengthen the cohesion of the core team and the competitiveness of the Company, align the interests of the shareholders, the Company and the core staff members, bring their attention to the long-term development of the Company and ensure that the Company's development strategy and business goals shall be realized, the 2023 A Share Incentive Scheme was approved by Shareholders' meeting of the Company.

(ii) Category of grantees and participants of the 2023 A Share Incentive Scheme

The total number of the eligible participants for the first grant proposed under the 2023 A Share Incentive Scheme shall be 295. All eligible participants must have an employment or labour relationship with the Company or its subsidiaries when a grant under the 2023 A Share Incentive Scheme is made and during the assessment period in relation to the First Grant and the Reserved Grant under the 2023 A Share Incentive Scheme.

None of the Directors, chief executive, members of senior management, non-PRC employees, shareholders who individually or collectively hold more than 5% of the Shares of the Company, de facto controllers, or their respective spouses, parents or children, or the respective associates of the Directors, substantial shareholders has been the grantee of any awards granted pursuant to the 2023 A Share Incentive Scheme.

(iii) Maximum entitlements of each participant and maximum number of Restricted A Shares to be issued by the Company under the 2023 A Share Incentive Scheme

None of the grants made under the 2023 A Share Incentive Scheme was subject to approval by the shareholders of the Company. The grants made under the 2023 A Share Incentive Scheme would not result in the awards granted and to be granted to each individual grantee in the 12-month period up to and including the date of such grant in aggregate to exceed 1% of the relevant class of shares in issue (excluding treasury shares (as defined under the Listing Rules)).

The maximum number of Restricted A Shares to be granted under the First Grant pursuant to the 2023 A Share Incentive Scheme would be 1,479,300 A Shares, representing approximately 90% of the A Shares available under the 2023 A Share Incentive Scheme, with the remaining 10%, being 164,400 A Shares reserved for further award grants. However, as a result of change of eligibility of four proposed participants, and the voluntary waivers of Restricted A Shares by nine proposed participants, the number of Restricted A Shares to be issued by the Company under the First Grant was adjusted from 1,479,300 A Shares to 1,444,500 A Shares, and was further adjusted to 2,166,750 A Shares (as adjusted after the implementation of the 2022 Capitalization of Reserve), representing approximately 0.12% of the Company's total number of issued Shares as of June 30, 2026. The number of Restricted A Shares to be issued by the Company under the Reserved Grant was adjusted from 164,400 A Shares to 246,600 A Shares (as adjusted after the implementation of the 2022 Capitalization of Reserve), representing approximately 0.01% of the Company's total number of issued Shares as of June 30, 2026. The total number of Shares to be granted to any participants under all the fully effective share incentive schemes of the Company shall not exceed 1% of the total share capital of the Company.

(iv) Grant price and the basis of determining the grant price

The Grant Price of the Restricted A Shares under the First Grant and the Reserved Grant shall be RMB28.58 per A Share (subject to adjustment).

Pursuant to the Shenzhen Listing Rules and the Management Measures, the grant price of the Restricted A Shares under the First Grant and the Reserved Grant shall be not less than the par value of the Shares, and in principle not less than the higher of:

1. 50% of the average trading price of the Company's A Shares for one trading day immediately preceding the date of the announcement in relation to the adoption of the 2023 A Share Incentive Scheme, being RMB28.51 per A Share; and

2. 50% of the average trading price of the Company's A Shares for the 20 trading days immediately preceding the date of the announcement in relation to the adoption of the 2023 A Share Incentive Scheme, being RMB28.58 per A Share.

The Grant Price was determined in accordance with the price references above mentioned. This was also determined with a view to stabilize talents and effectively incentivize employees under different cycles and business environments which may allow the Company to gain advantage in the competitive industry that it operates in. The Board has also taken into consideration the level of difficulty of the performance targets which participants must achieve for the Restricted A Share(s) to be vested, and considers that this is in balance with the discount in the Grant Price.

As a result of the implementation of the 2022 Profit Distribution Plan and 2023 Profit Distribution, and pursuant to the Management Measures and the 2023 A Share Incentive Scheme, on August 27, 2024, the Board has resolved to adjust the grant price of Restricted A Shares granted under the 2023 A Share Incentive Scheme from RMB28.58 per A Share to RMB18.65 per A Share.

As a result of the implementation of the 2024 Profit Distribution, and pursuant to the Management Measures and the 2023 A Share Incentive Scheme, on August 21, 2025, the Board has resolved to adjust the grant price of Restricted A Shares granted under the 2023 A Share Incentive Scheme from RMB18.65 per A Share to RMB18.45 per A Share.

(v) Granting of Restricted A Shares during the Reporting Period

No Restricted A Shares were granted under the 2023 A Share Incentive Scheme during the Reporting Period, and no further share incentives shall be available for grant under the 2023 A Share Incentive Scheme.

(vi) Vesting and Forfeiture of Restricted A Shares during the Reporting Period

The Company did not vest or forfeit any Restricted A Shares during the Reporting Period.

(vii) Particulars of movement of unvested awards during the Reporting Period

The granted Restricted A Shares shall be vested over a four-year period, with 25%, 25%, 25% and 25% of total shares vesting on the first trading date following each anniversary date after the vesting commencement date upon meeting certain performance conditions, and shall last until the last trading dates by the next anniversary date.

Set out below are details of the unvested awards and the movements of the number of granted awards under the 2023 A Share Incentive Scheme during the Reporting Period:

Category of grantee	Date of grant	Grant Price[1]	Number of unvested and not registered awards as at January 1, 2026	Number of awards vested during the Reporting Period	Number of awards cancelled/ forfeited during the Reporting Period	Number of unvested and not registered awards as at June 30, 2026
Employees	July 7, 2023	RMB18.45	910,946	0	0	910,946

Note:

(1) The grant price was adjusted from RMB18.65 to RMB18.45 as a result of the implementation of the 2024 Profit Distribution. Please refer to section under "(3) 2023 A Share Incentive Scheme – (iv) Grant price and the basis of determining the grant price" above for further details. Employees shall pay for the grant price of the vested Restricted A Shares based on the amount vested at the time of each vesting.

(viii) Remaining validity period of the 2023 A Share Incentive Scheme

The 2023 A Share Incentive Scheme shall be valid until the date on which all Restricted A Shares have been vested or forfeited, and such period shall not exceed 72 months. As such, as of June 30, 2026, the remaining life of the 2023 A Share Incentive Scheme is 36 months.

(ix) Others

As at June 30, 2026, the number of unvested and not registered awards is 910,946.

(4) Concluding statement

The total number of Restricted A Shares that may be issued in respect of awards granted under all A Share incentive schemes of the Company during the six months ended June 30, 2026 divided by the weighted average number of A Shares in issue for the six months ended June 30, 2026 was 0.1%.

H Share Award and Trust Schemes

(1) First H Share Award and Trust Scheme

The Shareholders have resolved to adopt the First H Share Award and Trust Scheme during the extraordinary general meeting of the Shareholders on December 11, 2020. The source of the award shares under the First H Share Award and Trust Scheme shall be H Shares to be acquired by the trustee through on-market transactions at the prevailing market price in accordance with the instructions of the Company and the relevant provisions of the relevant scheme rules.

(i) Purpose of First H Share Award and Trust Scheme

1. to attract, motivate and retain skilled and experienced personnel to strive for the future development and expansion of the Group by providing them with the opportunity to own equity interests in the Company;

2. to deepen the reform on the Company's remuneration system and to develop and constantly improve the interests balance mechanism among the Shareholders, the operational and executive management; and

3. to (a) recognize the contributions of the leadership of the Company including the Directors and long standing employees of the Company; (b) encourage, motivate and retain the leadership of the Company and long standing employees whose contributions are beneficial to the continual operation, development and long-term growth of the Group; and (c) provide additional incentive for the leadership of the Company and long standing employee by aligning the interests of the leadership of the Company to that of the Shareholders and the Group as a whole.

(ii) Category of grantees and participants of the First H Share Award and Trust Scheme

Eligible employees who may participate in the First H Share Award and Trust Scheme include any PRC or non-PRC employee, Director or consultant of any members of the Group.

None of the Directors, chief executive, shareholders who individually or collectively hold more than 5% of the Shares of the Company, de facto controllers, or the spouses, parents or children of such de facto controllers of the Company, or their respective associates has been the grantee of any awards granted pursuant to the First H Share Award and Trust Scheme.

(iii) Maximum entitlements of each participant and maximum number of H Shares to be granted by the Company under the First H Share Award and Trust Scheme

None of the grants made under the First H Share Award and Trust Scheme was subject to approval by the shareholders of the Company. The grants made under the First H Share Award and Trust Scheme would not result in the awards granted and to be granted to each individual grantee in the 12-month period up to and including the date of such grant in aggregate to exceed 1% of the Shares in issue.

Pursuant to the First H Share Award and Trust Scheme, the maximum number of H Shares that can be purchased on the market by the trustee appointed by the Company for the purpose of servicing the First H Share Award and Trust Scheme was 17,865,000 H Shares, and was adjusted to 35,563,910 H Shares on June 20, 2025, representing approximately 10.1% of the number of the Company's H Shares in issue (excluding any treasury H Shares) and approximately 1.9% of the total issued shares of the Company as of June 30, 2026.

The Company shall not make any further grant of award which will result in the aggregate number of H Shares underlying all grants made pursuant to the First H Share Award and Trust Scheme to exceed the scheme limit without Shareholders' approval. Award shares that have been forfeited in accordance with the First H Share Award and Trust Scheme shall not be added to the scheme limit, nor shall such forfeited shares be added to the total number of H Share granted under the First H Share Award and Trust Scheme.

(iv) Granting of H Shares during the Reporting Period

No H Shares were granted under the First H Share Award and Trust Scheme during the Reporting Period. As of June 30, 2026, there are 11,949,647 H Shares to be granted under the First H Share Award and Trust Scheme, which represents approximately 3.4% of the Company's total number of issued H Shares (excluding treasury H Shares) as of the same date.

(v) Vesting and Forfeiture of H Shares during the Reporting Period

On April 8, 2026, the Company vested a total of 222,054 H Shares to 31 eligible employees. A total of 9,849 H Shares that could be vested to 3 former employees were forfeited due to their resignations.

On June 3, 2026, the Company vested a total of 2,440,092 H Shares to 96 eligible employees. A total of 165,567 H Shares that could be vested to 11 former employees were forfeited due to their resignations.

Save as disclosed above, the Company did not vest or forfeit any H Shares granted under the First H Share Award and Trust Scheme during the Reporting Period.

(vi) Particulars of movement of unvested awards during the Reporting Period

Unless otherwise approved by the Board or the Delegatee, all granted H Shares shall be vested in four equal annual tranches of 25% each upon the corresponding anniversary of the grant date.

Set out below are details of the movements of the number of unvested awards under the First H Share Award and Trust Scheme during the Reporting Period:

Category of grantee	Date of grant	Grant Price	Number of unvested awards as at January 1, 2026	Number of Awards granted during the Reporting Period	Number of Awards vested during the Reporting Period	Number of Awards forfeited during the Reporting Period	Number of Awards cancelled during the Reporting Period	Number of unvested awards as at June 30, 2026
Employees	July 2, 2025[1]	N/A	5,396,470	0	0	0	0	5,396,470
Employees	July 2, 2025[2]	N/A	2,103,398	0	0	0	0	2,103,398
Employees	July 2, 2025[3]	N/A	3,217,500	0	0	0	0	3,217,500
Employees	May 31, 2022	N/A	2,605,659	0	2,440,092	165,567	0	0
Employees	April 1, 2022	N/A	231,903	0	222,054	9,849	0	0
Total			**13,554,930**	**0**	**2,662,146**	**175,416**	**0**	**10,717,368**

Notes:

(1) The 2025 First H Shares Employee Share Awards shall be vested over a four-year period, with 25%, 25%, 25% and 25% of total shares vesting on the first trading date after each anniversary date after the respective vesting commencement date upon meeting certain vesting conditions, and shall last until the last trading dates by the next anniversary date.

(2) The 2025 Second H Shares Employee Share Awards shall be vested over a two-year period with 50% and 50% of total shares vesting on the first trading date after each anniversary date after the respective vesting commencement date upon meeting certain vesting conditions, and shall last until the last trading dates by the next anniversary date.

(3) The 2025 Third H Shares Employee Share Awards shall be vested over a one-year period with 100% of total shares vesting on the first trading date after the anniversary date after the vesting commencement date upon meeting certain vesting conditions, and shall last until the last trading dates by the next anniversary date.

None of the grantees is a director or connected person of the Company or one of its five highest paid individuals during the Reporting Period, and none of the abovementioned grants was subject to approval by the shareholders of the Company.

(vii) Remaining validity period of the First H Share Award and Trust Scheme

The First H Share Award and Trust Scheme shall be valid and effective for a term commencing on the date on which the Shareholders and the Board approved the First H Share Award and Trust Scheme (being December 11, 2020), and ending on the business day immediately prior to the 10th anniversary of the Adoption Date, and after which no further awards will be granted, and thereafter for so long as there are any non-vested award shares granted hereunder prior to the expiration of the First H Share Award and Trust Scheme, in order to give effect to the vesting of such award shares or otherwise as may be required in accordance with the provisions of the rules of the First H Share Award and Trust Scheme. As such, as of June 30, 2026, the remaining life of the First H Share Award and Trust Scheme is 52 months.

(viii) Particulars of movement of unvested awards after the Reporting Period

On July 2, 2026, the Management Committee resolved to, subject to the relevant grantee's consent, cancel 5,396,470 H Share awards granted to 546 eligible employees pursuant to the 2025 First H Shares Employee Share Awards of the First H Share Award and Trust Scheme on July 2, 2025. This cancellation was due to a change in foreign exchange administrative policies. The Company has made a replacement grant under the 2025 H Share Award and Trust Scheme on substantially similar terms. Please refer to the Company's announcement dated July 2, 2026 and the section headed "(2) 2025 H Share Award and Trust Scheme – (vi) Particulars of movement of unvested awards after the Reporting Period" below for further details.

On July 31, 2026, the Company vested a total of 978,180 H Shares to 223 eligible employees pursuant to the 2025 Second H Shares Employee Share Awards of the First H Share Award and Trust Scheme. A total of 147,001 H Shares that could be vested to 18 former employees were forfeited due to their resignations.

On July 31, 2026, the Company vested a total of 3,217,500 H Shares to 25 eligible employees pursuant to the 2025 Third H Shares Employee Share Awards of the First H Share Award and Trust Scheme.

Set out below are details of the movements of the number of unvested awards under the First H Share Award and Trust Scheme after the Reporting Period and up to the date of this announcement:

Category of grantee	Date of grant	Grant Price	Number of unvested awards as at July 1, 2026	Number of Awards granted from July 1, 2026 and up to the date of this announcement	Number of Awards vested from July 1, 2026 and up to the date of this announcement	Number of Awards forfeited from July 1, 2026 and up to the date of this announcement	Number of Awards cancelled from July 1, 2026 and up to the date of this announcement	Number of unvested awards as at the date of this announcement
Employees	July 2, 2025	N/A	5,396,470	0	0	0	5,396,470	0
Employees	July 2, 2025	N/A	2,103,398	0	978,180	147,001	0	978,217
Employees	July 2, 2025	N/A	3,217,500	0	3,217,500	0	0	0
Employees	May 31, 2022	N/A	0	0	0	0	0	0
Employees	April 1, 2022	N/A	0	0	0	0	0	0
Total			**10,717,368**	**0**	**4,195,680**	**147,001**	**5,396,470**	**978,217**

None of the grantees is a director or connected person of the Company or one of its five highest paid individuals during the Reporting Period and up to the date of this announcement, and none of the abovementioned grants was subject to approval by the shareholders of the Company.

(2) 2025 H Share Award and Trust Scheme

The Shareholders have resolved to adopt the 2025 H Share Award and Trust Scheme during the annual general meeting of the Shareholders on June 20, 2025. The source of the award shares under the 2025 H Share Award and Trust Scheme shall be treasury H Shares repurchased in accordance with the instructions of the Company and the relevant provisions of the relevant scheme rules.

(i) Purpose of 2025 H Share Award and Trust Scheme

1. to attract, motivate and retain skilled and experienced personnel to strive for the future development and expansion of the Group by providing them with the opportunity to own equity interests in the Company;

2. to deepen the reform on the Company's remuneration system and to develop and constantly improve the interests balance mechanism among the Shareholders, the operational and executive management; and

3. to (a) recognize the contributions of the leadership of the Company including the Directors and long standing employees of the Company; (b) encourage, motivate and retain the leadership of the Company and long standing employees whose contributions are beneficial to the continual operation, development and long-term growth of the Group; and (c) provide additional incentive for the leadership of the Company and long standing employee by aligning the interests of the leadership of the Company to that of the Shareholders and the Group as a whole.

(ii) Category of grantees and participants of the 2025 H Share Award and Trust Scheme

Eligible employees who may participate in the 2025 H Share Award and Trust Scheme include any PRC or non-PRC employee (including consultant), Director (excluding any independent non-executive Director) of any members of the Group.

None of the Directors, chief executive, shareholders who individually or collectively hold more than 5% of the Shares of the Company, de facto controllers, or the spouses, parents or children of such de facto controllers of the Company, or their respective associates has been the grantee of any awards granted pursuant to the 2025 H Share Award and Trust Scheme.

(iii) Maximum entitlements of each participant and maximum number of H Shares to be granted by the Company under the 2025 H Share Award and Trust Scheme

None of the grants made under the 2025 H Share Award and Trust Scheme was subject to approval by the shareholders of the Company. The grants made under the 2025 H Share Award and Trust Scheme would not result in the awards granted and to be granted to each individual grantee in the 12-month period up to and including the date of such grant in aggregate to exceed 1% of the Shares in issue (excluding the number of treasury H Shares).

Pursuant to the 2025 H Share Award and Trust Scheme, the maximum number of H Shares issued or to be issued in connection with this Scheme shall not exceed 7,263,300 H Shares, representing approximately 2.1% of the number of the Company's H Shares in issue (excluding any treasury H Shares) and approximately 0.4% of the total issued shares of the Company as of June 30, 2026.

The Company shall not make any further grant of award which will result in the aggregate number of H Shares underlying all grants made pursuant to the 2025 H Share Award and Trust Scheme to exceed the scheme limit without Shareholders' approval. Award shares that have been forfeited in accordance with the 2025 H Share Award and Trust Scheme shall not be added to the scheme limit, nor shall such forfeited shares be added to the total number of H shares granted under the 2025 H Share Award and Trust Scheme.

(iv) Granting of H Shares during the Reporting Period

As of June 30, 2026, 7,263,300 H Shares had been repurchased and held as treasury H Shares by the Company, which are designated for utilization under the 2025 H Share Award and Trust Scheme. As of June 30, 2026, the Company had not made any grants under the 2025 H Share Award and Trust Scheme.

(v) Remaining validity period of the 2025 H Share Award and Trust Scheme

The 2025 H Share Award and Trust Scheme shall be valid and effective for a term commencing on the date on which the Shareholders and the Board approved the 2025 H Share Award and Trust Scheme (being June 20, 2025), and ending on the business day immediately prior to the 10th anniversary of such date, and after which no further awards will be granted, and thereafter for so long as there are any non-vested award shares granted hereunder prior to the expiration of the 2025 H Share Award and Trust Scheme, in order to give effect to the vesting of such award shares or otherwise as may be required in accordance with the provisions of the rules of the 2025 H Share Award and Trust Scheme. As such, as of June 30, 2026, the remaining life of the 2025 H Share Award and Trust Scheme is 108 months.

(vi) Particulars of movement of unvested awards after the Reporting Period

On July 2, 2026, the Management Committee resolved to grant an aggregate of 5,396,470 H Share awards to 546 eligible employees pursuant to the 2025 H Share Award and Trust Scheme. This grant replaces the 2025 First H Shares Employee Share Awards of the First H Share Award and Trust Scheme which were cancelled on the same date due to a change in foreign exchange administrative policies, and was made on substantially similar terms. To reflect the original vesting schedule of the 2025 First H Shares Employee Share Awards of the First H Share Award and Trust Scheme, the vesting period of the first tranche of this new grant began on July 2, 2026. Please refer to the Company's announcement dated July 2, 2026 and the section headed "(1) First H Share Award and Trust Scheme – (viii) Particulars of movement of unvested awards after the Reporting Period" above for further details.

On July 31, 2026, the Company vested a total of 1,294,505 H Shares to 523 eligible employees pursuant to the 2025 H Share Award and Trust Scheme. A total of 217,653 H Shares that could be vested to 23 former employees were lapsed due to their resignations.

Category of grantee	Date of grant	Grant Price	Number of unvested awards as at the date of grant	Number of Awards granted from July 1, 2026 and up to the date of this announcement	Number of Awards vested from July 1, 2026 and up to the date of this announcement	Number of Awards lapsed from July 1, 2026 and up to the date of this announcement	Number of Awards cancelled from July 1, 2026 and up to the date of this announcement	Number of unvested awards as at the date of this announcement
Employees	July 2, 2026[1]	N/A	0	5,396,470	1,294,505	217,653	0	3,884,312
Total			**0**	**5,396,470**	**1,294,505**	**217,653**	**0**	**3,884,312**

Note:

(1) The closing price of the H Shares immediately before the date on which the Awards were granted was HKD18.25.

14. Miscellaneous

(1) Appointment of Directors of the Fourth Session of the Board

On June 12, 2026, the Shareholders approved the Board's proposal to reduce the size of the Board from nine directors to eight. The restructured Board comprise three executive Directors, one employee representative Director, one non-executive Director and three independent non-executive Directors. The Shareholders also resolved to approve: (i) the respective appointments of Dr. LOU Boliang, Mr. LOU Xiaoqiang and Ms. ZHENG Bei as executive Directors of the fourth session of the Board; (ii) the appointment of Ms. WAN Xuan as non-executive Director of the fourth session of the Board; and (iii) the respective appointments of Ms. LI Lihua, Prof. TSANG King Fung and Ms. SHEN Rong as independent non-executive Directors of the fourth session of the Board. Separately, Mr. LI Shing Chung Gilbert was elected as the employee representative Director of the fourth session of the Board at the employee representatives' meeting held on June 5, 2026.

The term of office of each of the Directors of the fourth session of the Board will be three years commencing from the conclusion of the annual general meeting of the Company held on June 12, 2026. For details, please refer to the announcements of the Company dated April 28, 2026, June 5, 2026 and June 12, 2026, and the circular of the Company dated May 21, 2026.

(2) Placing of New H Shares under General Issuance Mandate

On January 14, 2026 (after trading hours), the Company entered into a placing agreement (the "**Placing Agreement**"), pursuant to which a total of 58,440,762 new H Shares (nominal value RMB1.00 each, aggregate nominal value RMB58,440,762) were placed at the price of HK$22.82 per H Share upon the terms and subject to the conditions set out in the Placing Agreement (the "**Placing**").

The Placing Price of HK$22.82 represented a discount of approximately 8.50% to the closing price of HK$24.94 per H Share as quoted on the Hong Kong Stock Exchange on January 14, 2026 (being the last trading day on which the Placing Agreement was signed).

The Board is of the view that the Placing will further a) enhance the Company's financial strength, enabling it to capture industry opportunities and support its capacity investment and business expansion, b) broaden the Company's Shareholder base, c) improve the trading liquidity of the Company's H Shares, and d) optimize the Company's capital structure by financing the repayment of a portion of its existing debts.

On January 22, 2026, the Placing was completed and the 58,440,762 new H Shares were placed to no less than six independent placees. The net price to the Company per Placing Share was approximately HK$22.57.

The aggregate gross proceeds from the Placing were approximately RMB1,197.9 million. The net proceeds from the Placing, after deducting relevant costs and expenses (including commission, levies and transactional fees), were approximately RMB1,184.5 million, and will be utilised in the following manner:

(1) approximately 70% will be used for the Company's project development to enhance the capabilities and production capacity of its laboratory services, drug process development and manufacturing facilities;

(2) approximately 10% will be used to repay bank loans and other borrowings, in order to optimise the Company's capital structure; and

(3) approximately 20% will be used to supplement the working capital and for other general corporate purposes.

The Company's utilisation of the net proceeds during the Reporting Period is set out below under the section headed "OTHER INFORMATION – B. Purchase, Sale or Redemption of the Company's Listed Securities".

For further details about the Placing, please refer to the Company's announcements dated January 15, 2026 and January 22, 2026.

(3) Investment Agreement with Hangzhou Qiantang Investment Service Center

In order to further expand the Group's production capacity for innovative drug commercial manufacturing and CDMO services, continuously strengthen its integrated service capability for new drug modality projects, on May 27, 2026, the Company entered into an Investment Agreement with Hangzhou Qiantang Investment Service Center (杭州市錢塘區招商服務中心), under which the Company plans to invest approximately RMB2.0 billion (the total project investment amount shall be subject to the final actual investment amount) to construct a new drug commercialization production and CDMO R&D production service facility in Qiantang District, Hangzhou, Zhejiang Province, the PRC. This investment will support the efficient conversion of CDMO service project pipelines towards late-stage clinical trial and commercialization stages, cultivate new growth drivers for the Company's sustainable development, and comprehensively enhance the Company's overall competitive advantages and market position. For further details, please refer to the Company's announcement dated May 27, 2026.

(4) Investment in the Construction of Campus II in Shaoxing

In order to further expand the Group's production capacity for high-end pharmaceutical intermediates and APIs (active pharmaceutical ingredients), consolidate its core business foundation and enhance service capabilities, in May 2026, the Company plans to construct Campus II in Shaoxing through its wholly-owned subsidiary Pharmaron (Shaoxing) API Manufacturing Co., Ltd. (康龍化成(紹興)新藥生產有限公司), to construct a project with an annual production capacity of 200 tonnes of pharmaceutical intermediates and APIs in Shaoxing City Hangzhou Bay Shangyu Economic and Technological Development Zone (紹興市杭州灣上虞經濟技術開發區).

The total investment in the project is expected to be approximately RMB3.0 billion, subject to the final actual investment amount. This investment will, through the use of advanced technical equipment, further expand the Company's production capacity for high-end pharmaceutical intermediates and APIs, including intermediates and APIs for drugs treating obesity and diabetes, oncology therapies and other products, strengthen the application capability of green manufacturing technologies, and enhance the Company's CDMO service capability from pre-clinical R&D to commercial manufacturing. For further details, please refer to the Company's announcement dated May 27, 2026.

(5) Entered into a Commercial Scale Manufacturing Collaboration Agreement for Formulation with a Large International Pharmaceutical Company

In March 2026, the Company and a large international pharmaceutical company jointly announced the entry into a commercial scale manufacturing collaboration agreement in respect of formulation of its first oral small-molecule GLP-1 receptor agonist filed for regulatory registration, which represented an important milestone in the Company's formulation CDMO business. The Company will leverage its platform advantages and is committed to providing efficient and reliable manufacturing services to help bring its innovative therapies to patients in China as soon as possible.

(6) Strategic Cooperation Agreement with Logical Qubit

In July 2026, the Company entered into a strategic cooperation agreement with Logical Qubit, through which the parties will explore cooperation models between quantum computing cloud platforms and pharmaceutical companies, including through the establishment of a joint laboratory, so as to drive the iterative upgrading of the pharmaceutical industry's R&D systems, technical standards and data systems towards a "Quantum-ready" state, and to lead the technological innovation of the industry. The Company will also work with Logical Qubit and Zhejiang University (浙江大學) to jointly explore the application of quantum computing in the field of drug discovery, with the aim of accelerating the process of computer-aided drug design and improving R&D service efficiency.

(7) Strategic Cooperation Agreement with AI² Robotics

In August 2026, the Company entered into a strategic cooperation agreement with AI² Robotics, an AGI-native general-purpose intelligent robotics company. The parties will establish an interdisciplinary joint research mechanism focused on the deep integration of embodied intelligence technologies into the life sciences and pharmaceutical R&D sectors. Through this collaboration, the parties will jointly explore the development of innovative and intelligent laboratories. The partnership aims to integrate embodied intelligent robots into real-world R&D and manufacturing workflows to support the intelligent transformation of the life sciences industry. As the relevant cooperation is still at an exploratory stage, the effectiveness of the technological applications and their impact on the Company are subject to uncertainties. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

(8) Additional Subscription of Investment Fund Units

To fully leverage the investment and industry insight capabilities of professional investment institutions, enhance the Company's investment capacity, seize quality opportunities in industry development, and promote the high-quality development of the pharmaceutical industry, in January 2026 and May 2026, the Company made additional investments of RMB50 million and RMB283 million respectively in Ningbo Yongkang Equity Investment Partnership (Limited Partnership) (寧波甬康股權投資合夥企業(有限合夥)) ("**Ningbo Yongkang**") using its own funds. Following the completion of the above additional investments, the Company's aggregate subscribed capital contribution to Ningbo Yongkang amounts to RMB433 million.

(9) Equity Restructuring of Aistarfish Technology and Kangsida

With a view to further streamlining the Company's business segments, optimising its equity structure and enhancing R&D efficiency and service quality, during the Reporting Period, the Company and its controlling subsidiaries, Pharmaron Clinical, LinkStart, Kangsida and Aistarfish Technology, entered into a series of restructuring agreements to carry out a series of equity adjustments in Aistarfish Technology and Kangsida, to the effect that the Company directly held 70.44% of the equity interest in Aistarfish Technology, which in turn fully held Kangsida. In February 2026, the Company completed the aforementioned equity restructuring.

(10) Changes in Accounting Policies

On April 28, 2026, the Audit Committee reviewed and approved the changes in accounting policies, in order to reflect the latest requirements of Interpretation No. 19 of Accounting Standards for Business Enterprises (Cai Kuai [2025] No. 32) issued in December 2025. For details, please refer to the announcement of the Company dated April 28, 2026.

On August 10, 2026 and August 20, 2026, respectively, the Audit Committee and the Board reviewed and approved the changes in accounting policies, according to the relevant requirements of Accounting Standards for Business Enterprises No. 35 – Segment Reporting, Interpretation No. 3 of the Accounting Standards for Business Enterprises, and the Company's business development and internal management needs. For details, please refer to the announcement of the Company dated August 20, 2026.

(11) Changes of Company Secretary, Authorised Representative and Process Agent

On March 30, 2026, Ms. Mak Po Man Cherie was appointed as the company secretary, the authorised representative and the process agent of the Company upon the resignation of Mr. Yim Lok Kwan. For details, please refer to the announcement of the Company dated March 30, 2026.

(12) 2025 Profit Distribution

On June 12, 2026, the 2025 Profit Distribution of the Company was approved at the annual general meeting of the Company. Pursuant to the 2025 Profit Distribution, the Company has paid a cash dividend of RMB0.2 per Share (inclusive of tax) to the Shareholders whose names appeared on the H Shares register of members of the Company on July 15, 2026 and Shareholders whose names appeared on the A shares register of members of the Company on July 6, 2026. For further details, please refer to the Company's circular dated May 21, 2026 and cash dividend announcement dated June 12, 2026.

(13) Amendments to the Articles of Association

On March 30, 2026, the Board resolved and approved to amend the Articles of Association to reflect the increase in the registered capital of the Company. For details, please refer to the announcement of the Company dated March 30, 2026.

On April 28, 2026, the Board resolved and approved to amend the Articles of Association to reflect the change in Board composition. For details, please refer to the announcement of the Company dated April 28, 2026.

C. Core Competitiveness Analysis

The Company provides customers with fully-integrated services covering drug research, development and manufacturing services for innovative pharmaceutical products throughout the research and development cycle. With this end-to-end and fully-integrated business model, we gain significant competitive advantages in deepening customer collaboration, establishing core technical expertise and professional team building which enable us to better support our customers' innovative R&D programs.

1. Industry-leading fully-integrated pharmaceutical R&D services platform with strong capabilities and provides comprehensive service offerings for customers across the globe

The Company is committed to building a R&D and manufacturing service platform across multiple therapeutic modalities (including small molecule, biologics and CGT products) throughout drug discovery, preclinical and clinical development process. The Company has a well-established and fully integrated R&D and manufacturing service platform for small molecule drugs, and is rapidly expanding into emerging drug modalities such as peptides, oligonucleotides, biologics, bioconjugate drugs and CGT products. The Company is in an industry-leading position in drug discovery, preclinical and early clinical-stage research, and has expanded its capabilities downstream to late clinical-stage development and commercial manufacturing. In the process of expanding its R&D service offerings, the Company has successfully transformed from a single laboratory chemistry service provider to an end-to-end, multiple modalities capable pharmaceutical R&D service platform with business operations in China, the U.K. and the U.S.

The Company has established comprehensive expertise in different R&D stages, so as to assist customers in accelerating their R&D programs and cater to a full spectrum of customers' needs. With our professional project management capabilities, we are able to utilize our full integrated services platform to cater for the customers' needs. Vertically, the Company is strengthening the seamless integration of the same disciplines across different pharmaceutical R&D stages. Horizontally, the Company is strengthening the integration of different disciplines at the same pharmaceutical R&D stages, improving the science and technology of each discipline, expanding the services offering, and promoting the interdisciplinary collaborations. With the integration and collaboration between our discovery and development service platforms, we have accumulated a profound understanding of the unique scientific challenges involved in our customers' new pharmaceutical R&D projects, which will facilitate us to move projects forward more efficiently and in turn maximize the benefits of our customers. The Company's profound industry knowledge, strong execution capability and end-to-end solutions will shorten the drug discovery and development cycle and reduce the associated risks for our customers.

As a fully-integrated pharmaceutical R&D service provider, the Company's comprehensive pharmaceutical R&D services platform has the following three core competences:

(1) Comprehensive integrated platform from drug discovery to IND application (Investigational New Drug)

From inception, the Company has been dedicated to establishing a fully integrated service platform from drug discovery to IND application, thereby assisting customers to accelerate their drug development process and reduce their overall R&D costs.

In laboratory chemistry services, the Company built a comprehensive chemistry platform for medicinal chemistry, synthetic chemistry, chemistry for new modalities, analytical and purification chemistry, computer-aided drug design (CADD), and early process chemistry. Laboratory chemistry provides customers

with chemistry services such as design and synthesis of compound library, discovery of hit and lead compounds, design and/or synthesis and optimization of lead compounds, synthesis of new modalities (nucleosides/nucleotides, lipids, saccharides, peptides, and conjugates), and chiral and non-chiral separation and purification, which fully cater to the diversified needs of different types of customers.

Bioscience services include laboratory protein production and characterization, structural biology, *in vitro* and *in vivo* DMPK/ADME, *in vitro* biology and *in vivo* pharmacology, safety assessment and bioanalytical services. Bioscience services provide customers with drug discovery services such as target validation, structural analysis, structure activity relationship studies, candidate compound identification, and druggability studies.

With this comprehensive services platform, the Company has undertaken many integrated research projects, and achieved a considerable number of milestones. In addition, the Company can also provide a customized service package at a particular stage of drug R&D process, for example, an integrated IND-enabling service package that includes preclinical safety assessment, early process development and manufacturing, pharmacology, DMPK and a scientifically sound and well-regulated clinical trial protocol. Leveraging its comprehensive IND enabling solutions, the Company offers customers IND filing support across multiple jurisdictions, thereby providing flexibility in regulatory strategy.

(2) A comprehensive CDMO platform from R&D to commercialization, supporting multiple drug modalities

Leveraging its deep expertise in small molecule R&D services and strategic expansion into biologics, the Company is committed to building a comprehensive CDMO service platform that spans the entire lifecycle from drug R&D to commercialization, addressing customers' process development and manufacturing needs across various drug modalities.

In small molecule CDMO services, the Company's experienced team offers customers comprehensive, end-to-end services, including process development and manufacturing of APIs, material science/pre-formulation, formulation development and manufacturing, and analytical development to satisfy preclinical, clinical, and commercial needs. The cGMP API and drug product manufacturing facilities of the Company are qualified to manufacture products to support clinical trials in global markets, including the U.S., China and the EU. Our quality assurance system follows the guidelines of the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH Guidelines) and supports the development and manufacture of APIs and pharmaceuticals meeting the regulatory requirements of FDA, NMPA and EMA, and can also support the preparation of complete regulatory data packages and documentation for regulatory filings and cGMP audits in U.S., EU, and Asia. For peptide drugs, the Company is expanding its manufacturing capabilities beyond laboratory synthesis and early-stage production to offer more comprehensive CDMO services. Its new solid-phase manufacturing suite for peptide APIs is on track for completion in the second half of 2026.

In biologics CDMO services, the Company offers customers cell line development, upstream and downstream process development, formulation development and fill-and-finish process development, and bioconjugation services, supported by analytics with method development. Regarding manufacturing capabilities, the Company provides drug substance and product manufacturing services armed with 200L to 2,000L production capacity to support projects from pilot to commercial stage production. In addition, building upon its expertise in linkers and payloads productions, the Company has established an integrated service platform for bioconjugate drugs, encompassing the entire chain of "antibody preparation – warhead molecule synthesis – linker synthesis – bioconjugation – bioanalysis", which provides integrated bioconjugate manufacturing services for early-stage clinical trial supplies. Meanwhile, the Company is strengthening its bioconjugation manufacturing capabilities for mid-to-late-stage clinical materials and commercial-scale production, including drug product formulation, offering customers fully integrated services from R&D through to commercialization.

In gene therapy CDMO services, the Company offers customers plasmid synthesis encoding therapeutic genes, cell line development, cell bank establishment, plasmid and cell production process development, formulation process development, manufacturing of products, analytical method development and validation, product-related impurities identification and analysis, stability evaluation, product analysis and GMP batch release, covering the entire gene therapy CDMO process.

(3) Fully-integrated clinical development services in China

The Company has built a sizeable and highly competitive clinical development services platform in China, offering customers complete, efficient, end-to-end Phase I, II, III and IV clinical development services. Its clinical development services include clinical site management, patient recruitment, regulatory affairs, medical affairs, clinical operations, pharmacovigilance, bioanalysis and clinical laboratory testing, quantitative pharmacology, data management and biostatistics, project management, and quality assurance. In addition, the clinical development service team collaborates with the preclinical and business development teams to get involved in clinical study planning discussions with customers as early as possible, to help customers accelerate the transition of their programs from preclinical R&D to clinical studies with high quality.

To support China customers in developing their innovative drug pipelines globally, the Company leverages its U.S.-based clinical pharmacology center, data management and biostatistics capabilities, bioanalytical platform, clinical CRO operations, and management teams well versed in the clinical development processes and cultural nuances of both China and the U.S. It offers a more efficient and convenient gateway for China customers to bring their R&D pipelines to global markets.

In addition, through its controlling subsidiary Aistarfish Technology's technological and data expertise in oncology, its proprietary digital and AI platforms with independent intellectual property rights, its case management system that strictly complies with international data privacy regulations (such as the Personal Information Protection Law, GDPR, and HIPAA), its strategic cooperation with the Chinese Society of Clinical Oncology (CSCO), and its real-world data (RWD) network covering more than 30 provinces across China, the Company has established unified multi-modal data standards. It integrates disease characteristics such as genomics and imaging to achieve cross-disease data integration. By optimizing patient screening and stratification through algorithms, it enhances the efficiency of innovative drug research and development throughout the entire process. Moreover, combined with Pharmaron's global network, it provides real-world study (RWS) services that meet the standards of the FDA and EMA for global pharmaceutical companies.

2. Global operations, profound experience in pharmaceutical R&D and state-of-the-art technologies to provide customized solutions for customers

The Company operates globally through our 28 operating facilities, clinical and manufacturing facilities in China, the U.K., the U.S. and Singapore, of which 12 operating facilities are located overseas. The Company's profound experience in global pharmaceutical R&D, together with its global operations and world-class technical capabilities offers our customers a unique value proposition and customized solutions that combines our technical expertise in different geographic locations and efficient services with seamless integration.

Through our global operation, the Company has established a services network and strategic presence in global life science hubs which enhances the customer communication and our understanding of customer needs. Further, by carrying out our R&D services under different jurisdictions, it provides flexibility to customize our services solutions that best suit our customers' geographic and strategic needs. For example, the clinical pharmacology team in U.S. has worked seamlessly with our Chinese team to help customers in China for the preparation and filing of IND application and conducted the first-in-human (FIH) studies in U.S. In addition, the Company's experience in regulatory filings in various jurisdictions and its service model of providing customers with end-to-end solutions enable our customers to file IND applications for their drug candidates in China, the U.S., or the EU in parallel, which makes the IND applications of our customers more flexible and efficient.

On the other hand, it is the Company's core strategy for each international acquisition to effectively integrate with our global services platform and brought in the world class talent and facilities into our integrated services platform to further strengthen our overall services capabilities and increase the efficiency of our services. These strategies complement each other to effectively improve the Company's international operation capability and bring high value-added services to customers.

Currently, the Company has established an integrated small molecule CDMO services platform across China, the U.K. and the U.S. Leveraging its global capacities, the Company is able to offer its global customers more flexible, scalable, and environmentally sustainable end-to-end API production services. In addition, through its associated company PharmaGend located in Singapore, the Company has further

enhanced its global deployment in late-stage and commercial drug product CDMO services. PharmaGend has passed inspections from the Food and Drug Administration of the U.S. (FDA) and the Health Sciences Authority (HSA) of Singapore, as well as the Qualified Person (QP) audit by Swissmedic (the Swiss drug regulatory authority). This represented a milestone of the Company's global drug product CDMO services and further strengthened its global services network.

By adhering to the long-standing growth strategy of building an "End-to-End, Fully-integrated, Globalized and Multiple Modalities Capable" platform with global footprints, it facilitates cross-regional and multiple regulatory jurisdictional collaboration on cross-disciplinary and cross-R&D stages projects. Meanwhile, with efficient project management and cross-cultural communication, it facilitates the collaborations among teams, regions and disciplines to maximize the interests of our customers.

3. Committed to utilizing innovative technologies to meet evolving R&D needs and increase efficiency

Since inception, the Company has continually put great emphasis on technology and innovation to fuel sustained business growth and meet evolving R&D needs. The Company develops new technologies through multiple measures such as internal research and development, collaboration with academic and professional institutions, customer collaboration and acquisitions. During the Reporting Period, the Company continued to increase investments in automation and artificial intelligence (AI) technologies to further strengthen its service capabilities. The Company actively explored automated synthesis technologies to conduct multi-step chemical reactions. These technologies aim to deliver compounds with greater efficiency and reduced manual intervention, and have achieved initial progress. In addition, the Company continued to promote the application of AI technologies, deeply integrating AI into synthesis route design, drug discovery, mechanism of action studies, toxicity prediction and data processing. By synergizing AI with automation, the Company increased experimental throughput, enhanced service efficiency, and minimized operational errors, thereby providing customers with faster, more accurate, and more reliable R&D data.

During the Reporting Period, the Company continued to strengthen its end-to-end healthcare service platform by promoting integration between its clinical and preclinical businesses and data and AI technologies. Leveraging its proprietary AI technology platform, the Company's controlling subsidiary Aistarfish Technology expanded integrated in-hospital and out-of-hospital cancer patient management services, and continued to strengthen AI capabilities in patient management and RWS services. During the Reporting Period, multiple research findings were presented at leading domestic and international academic conferences, further enhancing its expertise in AI healthcare technology and academic influence. On the business front, Aistarfish achieved meaningful scale in orders for real-world patient management and RWS services, and partnered with top-tier domestic hospitals for RWS collaborations. Additionally, through collaborations with the Company's clinical and preclinical business units, Aistarfish is actively building high-quality real-world data and multi-omics cohorts for precise patient populations, aiming to enhance the efficiency of innovative drug R&D processes for the Company's customers and post-market research efforts.

In terms of industry-academia-research collaborative innovation, in July 2026, the Company partnered with Logical Qubit and Zhejiang University to leverage the parallel computing power of quantum computing, aiming to achieve non-classical search in the chemical-biology space. This collaboration enables systematic and comprehensive exploration of high-potential drug candidates, accelerates the advancement of computer-aided drug design (CADD), and enhances the efficiency of R&D services.

4. Dedicated, stable and visionary management teams, experienced talent pools with progressive corporate culture

The Company's management team is led by Dr. LOU Boliang, our chairman and chief executive officer. With over 30 years of experience in the pharmaceutical industry, he is highly respected in the industry for his excellent leadership that contributes to the Company's rapid development. The Company's senior management team also has extensive work experience in the industry. The Company has more than 100 senior scientific and technical leaders, 4 of whom were named as National Talents and 17 of whom were named as Provincial-level Talents (including municipalities directly under the Central Government). Members of our highly skilled, experienced and international management team possess diverse expertise and extensive knowledge, and have significantly contributed to the growth of the Company's institutional knowledge base. The Company focuses on its homegrown scientific team consisting of selected, young and promising scientists, which enables us to form a cohesive and vibrant mid-level management team composed of nearly 5,000 technical managers and high-calibre scientific research talents across all scientific disciplines of the Company. In addition, the Company's visionary management team has established a highly experienced and skilled talent pool with strong execution efficiency. As of June 30, 2026, the Company had 24,953 R&D, production technology and clinical services staff in China, the U.K. and the U.S. The highly professional technical team ensures the Company's continuous provision of high-quality R&D services for customers. The open platform for talent development ensures that the Company will continuously attract talents from around the globe.

The Company is committed to its corporate philosophy of "Employee First and Customer Centric" which puts strong emphasis on employee training and improves all mechanisms so as to integrate their career development into the Company's overall development strategy. In order to develop and train our talents, the Company provides training to our employees through our inhouse training system including the "Pharmaron College", visiting scholar programs at renowned laboratories and institutions and holds various seminars, forums and academic symposiums regularly, through which our team members acquire updates on the most advanced technology and techniques of the industry. In addition, the Company has developed training programs with the world renowned universities and research institutes for high-calibre scientific research talent. The above measures have greatly improved the scientific research capabilities and cohesion of the Company and its employees. Furthermore, the Company respects and values every single customer so as to ensure R&D quality by tackling each technical challenge and complete every single task with integrity and scientific rigor.

Our dedicated, stable and visionary management team, experienced talent pool and outstanding corporate culture lay a solid foundation for the Company's long-term success.

5. Reputable, loyal and expanding customer base that contributes to our sustainable growth and business collaboration

The Company has a large, diverse and loyal customer base including the global top 20 pharmaceutical companies and numerous reputable biotech companies. In the first half of 2026, the Company introduced over 470 new customers, with over 98% of revenue contributed by the Company's large, diverse and loyal repeat customers. The Company's fully-integrated solution and deep understanding of customers' needs allow it to provide customized pharmaceutical R&D services for customers according to their needs. With further progress made in the existing customers' projects, the loyal and growing customer base will enable the Company to develop new services in drug development and at the early clinical stage.

The Company benefits from its strategic partnership with specific customers. Through know-how sharing and training provided during its deep collaboration with these customers, the Company is able to further improve technical capabilities and enhance service excellence, thereby creating a virtuous cycle. With our strong technical expertise, advanced infrastructure, profound industry knowledge, strong execution capability and quality customer services, the Company is able to become our customers' strategic partner and help them form their drug development or R&D outsourcing strategies, which in turn reinforces our close relationships with such customers. In addition to our strong scientific capabilities, the Company puts emphasis on areas like environmental protection, health, safety and intellectual property protection. The Company takes such measures as establishing an intellectual property protection system and building the information system to ensure that our customers' intellectual properties are well protected, and is widely recognized and trusted by customers in this respect. The Company's high-quality services enable it to accumulate a good reputation among our existing customers, and to further expand our customer base by acquiring new customers through word-of-mouth referrals.

OTHER INFORMATION

A. Employee Remuneration and Relations

As at June 30, 2026, the Group had a total of 27,316 employees, as compared to 25,088 employees as at December 31, 2025. The Group provides employees with competitive remuneration and benefits, and the Group's remuneration policies are formulated according to the assessment of individual performance and are periodically reviewed. The Group provides employees with opportunities to work on cutting-edge drug development projects with world-class scientists, as well as offer opportunities to continue academic learning in the Group's Pharmaron College.

B. Purchase, Sale or Redemption of the Company's Listed Securities

On January 22, 2026, the Company successfully placed an aggregate of 58,440,762 new H Shares to no less than six independent placees at the price of HK$22.82 per H Share. The net proceeds from the Placing amounted to approximately RMB1,184.5 million. As at June 30, 2026, the unutilized net proceeds amounted to RMB341.4 million. The net proceeds from the Placing have been and will be applied in accordance with the intended use set out in the announcement of the Company dated January 15, 2026, entitled "Placing of New H Shares under General Issuance Mandate". The table below sets out the proposed and actual use of the net proceeds from the Placing as at June 30, 2026:

Use of proceeds	**Percentage of allocation of net proceeds**	**Allocation of net proceeds** *(RMB million)*	**Utilized amount as at June 30, 2026** *(RMB million)*	**Unutilized net proceeds as at June 30, 2026** *(RMB million)*	**Expected timeline for utilizing the net proceeds**
The Company's project development to enhance the capabilities and production capacity of its laboratory services, drug process development and manufacturing facilities	70%	829.2	487.8	341.4	Expected to be fully utilized by December 31, 2026
Repaying bank loans and other borrowings, in order to optimise the Company's capital structure	10%	118.5	118.5	–	Fully utilised by 30 June 2026
Supplementing the working capital and for other general corporate purposes	20%	236.8	236.8	–	Fully utilised by 30 June 2026
Total	**100%**	**1,184.5**	**843.1**	**341.4**	

Note: Any discrepancies in the table between the total and the sum of the amounts listed are due to rounding.

Save as disclosed above, neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company's listed securities (including treasury shares) during the six months ended June 30, 2026.

C. Material Events after the Reporting Period

Save as disclosed in this announcement, there are no material events affecting the Company after the Reporting Period and up to the date of this announcement.

D. Compliance with the Model Code for Securities Transactions by Directors

The Company has adopted the Model Code as set out in Appendix C3 of the Listing Rules as its code of conduct for Directors' securities transactions. Having made specific enquiry with the Directors, all of the Directors confirmed that they have complied with the required standards as set out in the Model Code during the Reporting Period.

E. Compliance with the Corporate Governance Code

During the Reporting Period, the Company has complied with all the code provisions set forth in the Corporate Governance Code contained in Part 2 of Appendix C1 of the Listing Rules, with the exception that the roles of the chairman of the Board and the chief executive of our Company have not been segregated as required by code provision C.2.1 of Part 2 of the Corporate Governance Code. In view of Dr. LOU Boliang's experience, personal profile and his roles in our Company and that Dr. LOU has assumed the role of chief executive officer of our Company since our commencement of business, the Board considers it beneficial to the business prospect and operational efficiency of our Company that Dr. LOU assumes the roles of the chairman of the Board as well as the chief executive officer of our Company. The Board shall review the structure from time to time to ensure that the structure facilitates the execution of the Group's business strategies and maximizes the effectiveness of its operation.

F. Audit Committee

The Company established the Audit Committee with written terms of reference in compliance with Rule 3.21 of the Listing Rules and the Corporate Governance Code as set out in Appendix C1 to the Listing Rules.

From January 1, 2026 to June 12, 2026, the Audit Committee comprised three members, namely, Mr. YU Jian, Ms. LI Lihua and Prof. TSANG King Fung, all of whom are independent non-executive Directors of the Company. Mr. YU served as the chairman of the Audit Committee, who possesses suitable professional qualifications.

From June 12, 2026 up to the date of this announcement, the Audit Committee comprises three members, namely, Ms. LI Lihua, Prof. TSANG King Fung and Ms. SHEN Rong, all of whom are independent non-executive Directors of the Company. Ms. SHEN is the chairman of the Audit Committee, who possesses suitable professional qualifications.

The Audit Committee has reviewed the Company's unaudited interim condensed consolidated financial information of the Group for the Reporting Period and confirms that the applicable accounting principles, standards and requirements have been complied with, and that adequate disclosures have been made. The Audit Committee has also discussed internal control and financial reporting matters.

G. Publication of the Interim Results Announcement and Interim Report

The interim results announcement is published on the website of the Stock Exchange (www.hkexnews.hk) as well as the Company's website (www.pharmaron.com). The Group's 2026 interim report which contains all financial and other relevant information of the Company as required by the Listing Rules will be dispatched to Shareholders and published on the aforementioned websites in due course.

APPRECIATION

Lastly, I would like to thank all the staff and the management team for their hard work during the Reporting Period. On behalf of the Group, I would also like to express heartfelt gratitude to all of our users and business partners, and wish for their continuous support in the future. We will keep working closely with our Shareholders and employees to steer the Group to a more modernized and sophisticated level of operation, through which we aspire to open a new chapter in the Group's growth and development.

DEFINITIONS

"^{14}C"	Carbon-14 (^{14}C), or radiocarbon, a radioactive isotope of carbon with an atomic nucleus containing 6 protons and 8 neutrons
"^{3}H"	Tritium or Hydrogen-3, a radioactive isotope of hydrogen, whose nucleus contains one proton and two neutrons
"2020 Profit Distribution"	the distribution of the final dividends in respect of the year ended December 31, 2020, which was approved by the Shareholders at the 2020 annual general meeting of the Company held on May 28, 2021
"2021 A Share Incentive Scheme"	the 2021 Restricted A Share Incentive Scheme of the Company
"2021 Capitalization of Reserve"	the issue of 5 Capitalization Shares for every 10 Shares by way of capitalization of reserve which was approved by the Shareholders at the 2021 annual general meeting of the Company held on May 31, 2022
"2021 Profit Distribution"	the distribution of the final dividends in respect of the year ended December 31, 2021, which was approved by the Shareholders at the 2021 annual general meeting of the Company held on May 31, 2022
"2021 Profit Distribution Plan"	the 2021 Profit Distribution and 2021 Capitalization of Reserve
"2022 A Share Incentive Scheme"	the 2022 Restricted A Share Incentive Scheme of the Company
"2022 Capitalization of Reserve"	the issue of 5 Capitalization Shares for every 10 Shares by way of capitalization of reserve which was approved by the Shareholders at the 2022 annual general meeting of the Company held on June 21, 2023
"2022 Profit Distribution"	the distribution of the final dividends in respect of the year ended December 31, 2022, which was approved by the Shareholders at the 2022 annual general meeting of the Company held on June 21, 2023
"2022 Profit Distribution Plan"	the 2022 Profit Distribution and 2022 Capitalization of Reserve

"2023 A Share Incentive Scheme"	the 2023 Restricted A Share Incentive Scheme of the Company
"2023 Profit Distribution"	the distribution of the final dividends in respect of the year ended December 31, 2023, which was approved by the Shareholders at the 2023 annual general meeting of the Company held on June 6, 2024
"2024 Profit Distribution"	the distribution of the final dividends in respect of the year ended December 31, 2024, which was approved by the Shareholders at the 2024 annual general meeting of the Company held on June 20, 2025
"2025 H Share Award and Trust Scheme"	The 2025 H Share Award and Trust Scheme of the Company
"A Share(s)"	domestic shares of our Company, with a nominal value of RMB1.00 each, which are listed for trading on the Shenzhen Stock Exchange and traded in RMB
"ADC"	Antibody-drug Conjugate
"AI² Robotics"	AI Squared Robotics (Shenzhen) Co., Ltd (智平方(深圳)科技股份有限公司), established in 2023, is committed to the research and development of general-purpose embodied intelligent terminals
"Aistarfish Technology"	Aistarfish Technology Co., Ltd. (浙江海心智惠科技有限公司), a limited liability company incorporated in PRC on January 26, 2018, which is held as to 70.44% by the Company as of the date of this announcement
"Antibodies"	An immunoglobulin that specifically binds to a corresponding antigen
"API"	Active Pharmaceutical Ingredient, the component of a drug product that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body
"Audit Committee"	the audit committee of the Board
"Bioanalysis"	A sub-discipline of analytical sciences covering the quantitative analysis of xenobiotics (drugs, their metabolites, and biomolecules at unusual locations or concentrations) and biotics (macromolecules, proteins, DNA, biologics, metabolites) in biological systems
"Biocatalysis"	the chemical reaction process mediated by enzymes as catalysts
"Bioconjugation"	a chemical method that involves creating a stable link, typically covalent, between two molecules, at least one of which is of biological origin or a derivative of a biomolecule. This technology is widely used in fields such as drug development, biomedical research, and clinical diagnosis

"Biostatistics"	the business of data management and biostatistics
"Bispecific Antibodies"	Bispecific Antibody (BsAb) refers to an engineered antibody capable of simultaneously binding to two distinct targets or epitopes
"Board"	the board of Directors of the Company
"Campus I in Ningbo"	Located in Qianwan New Area, Ningbo City, Zhejiang Province, it is mainly engaged in laboratory services and CDMO services
"Campus I in Shaoxing"	Located in Shangyu Area, Shaoxing City, Zhejiang Province, it is mainly engaged in CDMO services
"Campus II in Shaoxing"	Located in Shangyu Area, Shaoxing City, Zhejiang Province, it is mainly engaged in CDMO services
"Campus III in Beijing"	Located in Beijing Economic-Technological Development Area, it is mainly engaged in laboratory services and CDMO services
"Campus III in Ningbo"	Located in Qianwan New Area, Ningbo City, Zhejiang Province, it is mainly engaged in laboratory services
"Campus IV in Ningbo"	Located in Qianwan New Area, Ningbo City, Zhejiang Province, it is mainly engaged in laboratory services
"CDMO"	Contract Development and Manufacturing Organization (CDMO) services refer to services provided to innovative drug developers, including the development, design and optimization of pharmaceutical manufacturing processes, as well as customized manufacturing services ranging from kilogram-scale to tonne-scale production for pre-clinical development, clinical development and commercialization
"cGMP"	Current Good Manufacturing Practice
"Clinical research"	The clinical research of innovative drugs is divided into four stages from I to IV. The work involves the whole process of clinical trial, including the preparation before the trial, the selection of clinical trial research institutions and investigators, assisting the sponsor to prepare for the deliberation of the ethics committee, and working with the sponsor and investigators to design and implement the clinical trial protocol
"Commercialization"	The stage of drug development when a new drug is approved and marketed
"Company" or "Pharmaron"	Pharmaron Beijing Co., Ltd. (康龍化成(北京)新藥技術股份有限公司), a joint stock limited company incorporated under the laws of the PRC on July 1, 2004, the A Shares of which are listed on the Shenzhen Stock Exchange (stock code: 300759) and the H Shares of which are listed on the Main Board of the Hong Kong Stock Exchange (stock code: 3759)

"CRC"	Clinical Research Coordinator
"CRO"	Contract Research Organization
"Crystal screening"	Adopt high-throughput screening technology to obtain various types of solid forms that may exist in the drug, characterize the physicochemical properties of various forms using a variety of solid-state analytical techniques, and adopt multidisciplinary and comprehensive means to assess the biopharmaceutical performance of the advantageous forms, in order to screen out the advantageous crystalline forms of the drug that are suitable for production, high bioavailability, and conducive to the preparation of the drug
"De facto controllers"	LOU Boliang, LOU Xiaoqiang, ZHENG Bei
"Directors"	directors of the Company
"Druggability"	Preliminary pharmacodynamic studies, early evaluation of pharmacokinetic properties and safety, with potential for development as a drug
"EMA"	European Medicines Agency, an EU agency for the evaluation of medicinal products
"ESG"	Environmental, Social and Governance
"FDA"	the Food and Drug Administration of the U.S.
"FIH"	Including Phase I clinical studies that evaluate the pharmacokinetics, safety and tolerability of investigational drugs in humans
"First H Share Award and Trust Scheme"	The First H Share Award and Trust Scheme of the Company
"GDPR"	The General Data Protection Regulation (GDPR), being a data protection regulation enacted by the European Union, which aims to regulate the processing of personal data and strengthen the protection of personal privacy rights
"GLP-1"	Glucagon-Like Peptide-1 (GLP-1) refers to an important gut hormone involved in blood glucose regulation, appetite control, and energy metabolism
"GLP-1 receptor agonist"	GLP-1 receptor agonist refers to a class of drugs that activate the GLP-1 receptor to modulate blood glucose metabolism and appetite, primarily indicated for the treatment of metabolic diseases such as diabetes and obesity

"GMP"	Good Manufacturing Practice refers to a series of quality, hygiene and safety management measures implemented in the pharmaceutical production process, covering the entire drug production process, from raw materials, personnel, facilities and equipment, and production processes to packaging and transportation
"Group", "we", "our" or "us"	the Company and its subsidiaries from time to time
"H Share(s)"	overseas-listed foreign shares in the share capital of our Company, with a nominal value of RMB1.00 each, which are listed for trading on the Hong Kong Stock Exchange and traded in HK dollars
"HIPAA"	The Health Insurance Portability and Accountability Act (HIPAA), being a healthcare data protection law enacted by the United States, which regulates the collection, use, storage, transmission and disclosure of Protected Health Information (PHI)
"Hit and lead compound"	Compounds identified through screening during the drug discovery phase that are capable of interacting with specific target(s) and demonstrating preliminary pharmacological activity serve as an important foundation for the discovery and optimisation of lead compounds
"IND application"	investigational new drug. It refers to an application for an experimental drug that allows a pharmaceutical company to conduct clinical trials prior to obtaining approval for marketing
"Induced Proximity Therapeutics"	Induced Proximity Therapeutics refers to a class of innovative drugs that induce proximity interactions between a target protein and a specific functional protein, thereby achieving degradation or functional modulation of the target protein
"Kangsida"	Beijing Kangsida Health Management Co., Ltd.(北京康斯達健康管理有限公司), a company incorporated in PRC on April 15, 2014, which is indirectly held as to 70.44% by the Company as of the date of this announcement
"Lead compound"	A compound with certain strength and selective activity against a certain target or model, which generally has a novel chemical structure, and its physical and chemical properties, pharmacokinetic properties and safety meet certain requirements, so it has the property of analogy and exploitability. Generally, lead compounds can not be directly used as drugs, and their chemical structures need to be optimized to achieve the best configuration of the above properties. The quality of lead compounds directly affects the speed and success rate of new drug research and development
"Linker"	A component of an ADC that links antibodies to toxic molecules

"LinkStart"	Beijing LinkStart Med-Tech Co., Ltd.(北京聯斯達醫藥科技發展有限公司), a company incorporated in PRC on July 19, 2012, which is held as to 84.44% by the Company
"Listing Rules"	the Rules Governing the Listing of Securities of the Stock Exchange
"Logical Qubit"	Hangzhou Logical Qubit Technology Co., Ltd.(杭州邏輯比特科技有限公司), which was established in 2022 and is principally engaged in the design, fabrication and control of superconducting quantum processor
"Management Committee"	the management committee of the First H Share Award and Trust Scheme and 2025 H Share Award and Trust Scheme to which the Board has delegated its authority to administer the First H Share Award and Trust Scheme and 2025 H Share Award and Trust Scheme
"Management Measures"	the Management Measures for Share Incentives of Listed Companies
"MHRA"	U.K. Medicines and Healthcare products Regulatory Agency
"Model Code"	the Model Code for Securities Transactions by Directors of Listed Issuers
"Monoclonal antibodies"	Monoclonal Antibody (mAb) refers to an engineered antibody capable of specifically recognising and binding to a specific epitope
"Multispecific Antibodies"	Multispecific Antibody refers to an engineered antibody capable of simultaneously binding to two or more distinct targets or epitopes
"NMPA"	National Medical Product Administration (國家藥品監督管理局) (formerly known as China Food and Drug Administration), the authority responsible for approving drug and biologic products in China
"Oligonucleotides"	A compound in which nucleotides are linked by phosphodiester bonds
"Peptide"	A compound of amino acids linked by peptide bonds
"Pharmacovigilance"	Scientific research and activities related to the detection, evaluation, understanding and prevention of adverse reactions or any other problems that may be related to drugs
"Pharmaron Clinical"	Pharmaron (Chengdu) Clinical Services Co., Ltd. (康龍化成(成都)臨床研究服務有限公司), a company incorporated in PRC on May 27, 2021, which is held as to 84.44% by the Company
"Plasmid"	Double-stranded circular DNA, a common vector used in genetic engineering

"PRC"	the People's Republic of China
"Preclinical"	Of or relating to the preclinical stage of drug research
"R&D"	research and development
"Reporting Period"	the six months ended June 30, 2026
"Restricted A Shares"	the restricted A Shares granted by our Company under the respective 2021 A Share Incentive Scheme, 2022 A Share Incentive Scheme and 2023 A Share Incentive Scheme
"RMB"	Renminbi, the lawful currency of the PRC
"Share(s)"	A Share(s) and H Share(s)
"Shareholder(s)"	the holder(s) of the Share(s)
"Shenzhen Listing Rules"	the Rules Governing the Listing of Stocks on the ChiNext Market of Shenzhen Stock Exchange
"Solid-phase synthesis"	Solid-Phase Synthesis refers to a chemical synthesis technique that utilizes an insoluble solid support as the reaction support, progressively constructing the target molecule through iterative cycles of reaction steps such as coupling and deprotection.
"SSU"	Study Start up, the start-up specialist of a clinical project
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"Structure activity relationship"	The relationship between the chemical structure of drugs or other physiologically active substances and their physiological activities is one of the main research contents of medicinal chemistry
"Synthetic process"	A single or multi-step unitary reaction process that converts a specific raw material to a desired product. Synthesis routes are generally discussed in relation to specific products
"Target"	Biological macromolecules, such as some proteins and nucleic acids, which have pharmacodynamic functions *in vivo* and can be acted on by drugs. Those genes encoding target proteins are also known as target genes. The prior identification of target molecules associated with specific diseases is the basis of modern new drug development
"TQT/cardiac"	This study means observing and describing all ECG changes of the subject in an all-round manner at the early stage of a clinical trial on the drug and measuring the extension of the QT/QTc interval to determine whether the drug will impact the heart repolarization and the extent of impact, judge the risk of malignant arrhythmia it will trigger, and provide the data support in deciding whether to enter the next drug research and development stage

"U.K."	the United Kingdom
"U.S."	the United States
"US$" or "USD"	United States dollars, the lawful currency of the United States
"XDC"	Broadly defined drug conjugate (X-Drug Conjugate) refer to a class of drugs formed by conjugating a payload with a targeting molecule via a linker, which include antibody-drug conjugate (ADC), antibody-oligonucleotide conjugate (AOC), peptide-drug conjugate (PDC), and radionuclide drug conjugate (RDC), among others
"%"	per cent.

By order of the Board
Pharmaron Beijing Co., Ltd.
康龍化成(北京)新藥技術股份有限公司
Dr. Lou Boliang
Chairman

Beijing, the PRC
August 20, 2026

As at the date of this announcement, the Board of Directors comprises Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei as executive Directors; Mr. Li Shing Chung Gilbert as employee representative Director; Ms. Wan Xuan as non-executive Director; Ms. Li Lihua, Prof. Tsang King Fung and Ms. Shen Rong as independent non-executive Directors.